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Neuroinflammation can lead to neuronal dysfunction and degeneration as found in 
many neurological diseases.  Our lab has demonstrated that acetate supplementation is 
anti-inflammatory and neuroprotective in rat models of neuroinflammation and Lyme 
neuroborreliosis.  Acetate supplementation in rats through oral administration of glyceryl 
triacetate (GTA) increases plasma acetate and brain acetyl-CoA levels.  Acetyl-CoA is a 
ubiquitous substrate for several biochemical pathways including carbohydrate, protein, 
and lipid metabolism and labeled-acetate is incorporated into the purine and lipid pools.  
However, the effect(s) that acetate supplementation has on brain purine and lipid content 
have not been quantified.  To determine the effects that GTA has on brain energy levels, 
we measured nucleotide, phosphagen, and glycogen levels, using high performance liquid 
chromatography (HPLC) and a fluorometric assay.  Further, we used gas chromatography 
to quantify brain cardiolipin content and electron microscopy to quantify neuronal 
mitochondria in order to test the effects of GTA on mitochondrial biogenesis.  With 
single-dose acetate supplementation, we observed increase in brain phosphocreatine 
(PCr) and reduction in AMP levels at 4 h.  No changes in other brain nucleotides and 
glycogen were observed which is consistent with the normal state of rats used in this 
study.  Long-term acetate supplementation did not alter brain glycogen levels, 
mitochondrial number in CA3 neurons or whole brain cardiolipin mass.  Based on these 
results, we measured the effect of long-term GTA in normal and LPS-induced 
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neuroinflammation rats on brain nucleotide, and phosphagen levels.  Unlike single-dose 
GTA, no significant changes were found in PCr and nucleotide levels.   
Nonetheless, single-dose acetate supplementation reduced AMP levels and its 
breakdown product, adenosine, is a potent neuromodulator with anti-inflammatory 
properties.  Therefore, we postulated that long-term acetate supplementation may reduce 
neuroinflammation by increasing adenosine formation as a result of altered purinergic 
metabolism.  To begin to test this hypothesis, we quantified the ability of acetate to alter 
brain levels and activity of ecto-5’-nucleotidase (CD73), and the levels of adenosine 
kinase (AK) and adenosine A2A receptors using Western blot analysis and HPLC-based 
analysis of nucleotide hydrolysis.  We also examined how protein levels and activity 
differed using both prophylactic and interventional treatment strategies.  Prophylactic 
acetate supplementation prevented the LPS-induced reduction of brain CD73, increased 
CD73 activity, and prevented the LPS-induced increase in AK and A2A levels.  
Interventional GTA treatment also increased CD73 and A2AR levels compared to non-
treated controls.  To better understand the cell types involved in acetate-induced 
modulation of adenosine metabolizing enzymes and receptors, we quantified ecto-apyrase 
(CD39), CD73, AK, and adenosine deaminase (ADA) enzymes, and adenosine A1 and 
A2A receptor levels using Western blot analysis in BV2 microglia and primary astrocytes.  
In BV2 microglia, we found that LPS-induced increase in CD73, AK and A2A receptor 
levels were prevented by acetate while CD39, ADA, and A1 levels were reduced below 
control levels with acetate in presence of LPS.  Astrocytes, on the other hand, showed 
that CD73 and AK levels were increased with acetate treatment in presence of LPS 
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however CD39, ADA, and A2A levels were not altered by acetate plus LPS.  Furthermore, 
to determine the effect that altered purinergic enzyme levels have on adenosine formation 
we measured extracellular adenosine levels in both BV2 microglia and astrocyte cultures 
using HPLC after acetate and/or LPS stimulation.  However, we did not find any changes 
in extracellular levels of adenosine in microglia as well as astrocytes.  The lack of 
elevation in extracellular adenosine levels may be due to rapid adenosine turnover or 
disrupted paracrine signaling in isolated microglia and astrocyte cultures.  However, 
overall these data support the hypothesis that acetate supplementation can modulate 
adenosine metabolism and reduce A2A receptor levels that may contribute to its anti-
inflammatory properties.   
Lastly, we investigated the effect of acetate in the presence and absence of LPS 
on fatty acid, phospholipid, and cholesterol content of BV2 microglia in order to 
demonstrate whether acetate-induced acetyl-CoA can stimulate lipid synthesis.  Using 
gas chromatography we found that 1, 5, and 10 mM of acetate in presence of LPS at 2 h 
increased the fatty acid content of BV2 cells.  However, this increase did not result in 
altered phospholipid levels as measured by the phosphorus content of individual 
phospholipid classes.  A colorimetric assay for cholesterol showed a modest increase in 
cholesterol levels with 5 mM acetate.  Overall these data suggest that acetate 
supplementation stimulates purine and lipid metabolism in brain and glial cultures which 







Acetate supplementation attenuates markers of inflammation in rat models of 
neuroinflammation (Reisenauer et al. 2011) and Lyme neuroborreliosis (Brissette et al. 
2012), improves the tremor phenotype in a Canavan disease model (Arun et al. 2010b), 
offers metabolic support in a brain trauma model (Arun et al. 2010a), and possesses 
growth arresting properties in gliomas (Tsen et al. 2013).  Acetate supplementation in 
animals is induced by oral glyceryl triacetate (GTA) administration which increases rat 
plasma acetate and brain acetyl-CoA levels (Reisenauer et al. 2011).  Acetyl-CoA, the 
metabolically active form of acetate, is a substrate used for various biochemical pathways 
including carbohydrate, lipid, and protein metabolism.  Hence, gaining a better 
understanding about the role of GTA in altering acetyl-CoA pathways can provide 
mechanistic insights into the protective effects of acetate supplementation.   
With regard to protein metabolism, GTA increases brain histone acetylation 
(Soliman & Rosenberger 2011) and reverses the bacterial lipopolysaccharide (LPS)-
induced hypoacetylation of histone 3 at lysine 9 (H3K9) (Soliman et al. 2012b).  Further, 
acetate-induced changes in histone acetylation are associated with altered cytokine 
expression and reduced inflammatory signaling in glial cultures (Soliman et al. 2013a, 
Soliman et al. 2012a).  Nonetheless, acetate-induced acetyl-CoA levels through the 
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tricarboxylic acid (TCA) cycle and lipid synthesis pathways may contribute to the 
beneficial properties of acetate supplementation.  Although, radio-labeled acetate gets 
incorporated into the TCA cycle (Wyss et al. 2011), the fatty acid synthesis (Howard et 
al. 1974) and the cholesterol synthesis pathways (Hellman et al. 1954), the direct effect 
that a significant increase in circulating levels of acetate has on brain purine and lipid 
metabolism remains unknown.   
 
Disruption of brain energy metabolism and available energy sources 
The central nervous system (CNS) depends on mitochondrial energy production 
to maintain normal physiological functions like cellular homeostasis and compartment 
integrity, intracellular trafficking, formation and uptake of neurotransmitters, 
neurotransmission and energy-dependent anabolic reactions (Ames 2000, Morais & De 
Strooper 2010).  Disruption of mitochondrial function leads to partial plasma membrane 
depolarization, activation of NMDA receptors, excitotoxicity, and neuronal death 
(Novelli et al. 1988).  Glucose and energy metabolism are reduced with increases in 
extracellular glutamate content and receptor numbers in the aging brain (Hoyer 1990), 
making it more vulnerable to anoxic damage (Roberts & Chih 1995).  As early as 1 min 
following ischemia, brain ATP and phosphocreatine (PCr) levels fall (Lowry et al. 1964), 
and reduced PCr levels are observed in Alzheimer’s disease patients presenting with mild 
dementia (Pettegrew et al. 1994).  Neurons use PCr to store energy as a reserve which 
when required is readily converted to ATP (Meyer et al. 1984).  Increasing neuronal PCr 
stores protects neurons from hypoxic damage, glutamate toxicity, amyloid β-induced 
toxicity (Balestrino et al. 2002, Balestrino et al. 1999, Brewer & Wallimann 2000) and is 
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neuroprotective in animal models of Huntington’s disease (Matthews et al. 1998), 
Parkinson’s disease (Matthews et al. 1999), and amyotrophic lateral sclerosis (Klivenyi et 
al. 1999).  Moreover, direct application of ATP and PCr not only increase α-processing 
of amyloid-β precursor protein (APP) in SH-SY5Y cells, but also improve inefficient 
APP α-processing in aged human fibroblasts (Sawmiller et al. 2012).   
In brain, acetate is preferentially utilized by astrocytes (Waniewski & Martin 
1998) and is considered as a glial-specific substrate since labeled-acetate is mainly 
incorporated into the synthetic astrocytic-glutamine pool (Minchin & Beart 1975).  
During increased metabolic demand neurons depend on astrocytes for rapid removal of 
potassium ions and neurotransmitters from the extracellular space to maintain neuronal 
activity (Brown 2004).  This results in an overall increase in energy demand by both 
neurons and astrocytes where astrocytic glycogenolysis may play an important role.  
Astrocytic glycogen can serve as an important energy reserve to support neuronal energy 
metabolism by sparing extracellular glucose for neuronal utilization (Dinuzzo et al. 
2012).  However, the influence that utilization of acetate through the TCA cycle has on 
normal brain energetics has not been demonstrated.   
 
Ketogenic diet and brain energy metabolism 
A close metabolic correlate to acetate supplementation with regard to brain 
bioenergetics is the ketogenic diet which increases cellular acetyl-CoA levels (Yudkoff et 
al. 2005).  The ketogenic diet is a high-fat low-carbohydrate diet used to treat refractory 
cases of epilepsy and is considered neuroprotective (Bough et al. 2006).  While the 
mechanisms underlying the therapeutic effect of the diet remain unknown, a variety of 
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studies suggest mitochondrial bioenergetics to be the key in this regard (Maalouf et al. 
2009).  Ingestion of the diet produces ketone bodies that cross the blood brain barrier and 
are metabolized to acetyl-CoA, which increases mitochondrial biogenesis in hippocampal 
neurons and improves brain ATP production (Bough et al. 2006, Nylen et al. 2009).  
Mitochondrial biogenesis is a process that stimulates the synthesis of mitochondria, 
import of nuclear-encoded proteins, and fusion of organelles to form a network that 
increases metabolic function (Nisoli & Carruba 2006).  Cardiolipin, a phospholipid class, 
mainly located in the inner mitochondrial membrane (Daum 1985) is involved in the 
regulation of mitochondrial bioenergetics (Hoch 1992), is important for the activity of 
mitochondrial proteins, and can be used as a marker for quantifying mitochondrial mass 
(Houtkooper & Vaz 2008, Schlame 2007).  Since both acetate supplementation and the 
ketogenic diet increase tissue acetyl-CoA levels it is important to study the effects of 
GTA on mitochondrial biogenesis. 
 
Neuroinflammation: link to energy metabolism 
Neuroinflammation is a common feature shared by many neurodegenerative 
diseases including Alzheimer, Parkinson, Huntington, amyotrophic lateral sclerosis, and 
multiple sclerosis (Forman et al. 2004).  Inflammation is a self-defense mechanism that 
involves a complex cascade of biological responses directed towards a noxious tissue 
insult or damage in order to promote clearance of tissue debris and repair.  CNS-
inflammation is characterized by activation of neuroglia and associated changes in gene 
expression leading to production and release of pro-inflammatory mediators such as 
cytokines, prostaglandins, nucleotides, glutamate, nitric oxide, reactive oxygen species 
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(ROS), and proteases (Hanisch 2002).  Microglia, the innate immune cells of the CNS, 
upon activation release pro-inflammatory mediators and constitute the acute 
inflammatory response.  This is accompanied by the release of anti-inflammatory 
cytokines, lipoxins, resolvins and neuroprotectins (Block et al. 2007, Olson & Miller 
2004) which help in resolving inflammation.  On the other hand astrocytes, the major cell 
type in the brain, play a key role in maintaining CNS homeostasis and mediating 
neuroinflammation (Farina et al. 2007).  However, prolonged and uncontrolled 
neuroinflammatory response to a persistent stimulus or due to disrupted regulation of 
inflammatory mediators is thought to be responsible for the progressive nature of various 
neurodegenerative diseases (Gao & Hong 2008).  
Progressive loss of cellular energy and mitochondrial dysfunction are reported in 
several neurological disorders and aging (Beal 1995, Di Filippo et al. 2010).  Although a 
direct link between CNS inflammation and energy levels has not been established, 
mitochondrial dysfunction is a common feature associated with both neuroinflammation 
and neurodegeneration.  Mitochondrial dysfunction and neuroinflammation are thought to 
synergistically trigger a vicious cycle of deleterious effects eventually leading to neuronal 
death (Di Filippo et al. 2010).  Interestingly, pharmacological inhibition of mitochondrial 
components is widely used to induce neuroinflammation and neurodegeneration in 
experimental models (Di Filippo et al. 2006).  Therefore, increasing cellular energy has 
the potential to improve resistance against metabolic insults and slow the progression of 
neuroinflammation in neurodegenerative conditions.  In this regard, acetate 
supplementation prevents ATP loss in a traumatic brain injury model (Arun et al. 2010a) 
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however to date it has not been demonstrated whether neuroinflammation or acetate 
supplementation can directly alter brain energy levels. 
 
Rat model of neuroinflammation 
A reproducible model of neuroinflammation is generated in rats by infusing a 
Gram-negative bacilli endotoxin, LPS directly into the 4
th
 ventricle of the brain (Hauss-
Wegrzyniak et al. 1998a, Hauss-Wegrzyniak et al. 1998b).  In brain, LPS binds to the 
TLR4/CD14/MD-2 receptor complex (Fujihara et al. 2003) that activates neuroglia, 
reduces cholinergic immuno-reactivity (Reisenauer et al. 2011), and increases the 
expression of the pro-inflammatory cytokine interleukin (IL)-1β (Soliman et al. 2012b).  
Increased brain arachidonic acid turnover with increased activity of arachidonic acid-
selective secretory and cytosolic phospholipase A2 and levels of prostaglandins are 
observed in this model (Hauss-Wegrzyniak et al. 1998a, Hauss-Wegrzyniak et al. 1998b, 
Hauss-Wegrzyniak et al. 2000, Lee et al. 2004, Rosenberger et al. 2004).   
 
Purinergic signaling and neuroinflammation 
Purines comprise of adenine and guanine nucleobases that are the basic units of 
nucleosides and nucleotides.  Of these the adenine nucleoside (adenosine) and 
nucleotides (ATP, ADP, and AMP) are most widely studied.  Adenine nucleotides are the 
basic energy storage units of the cell, which upon breakdown result in adenosine 
formation and help maintain cellular energy balance (Shepel et al. 2005).  The production 
of adenosine increases with increased energy consumption and is inversely correlated to 
the energy charge ratio [(ATP+0.5*ADP)/ (ATP+ADP+AMP)] (Shepel et al. 2005), the 
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metabolically available energy to a cell at any given time (Atkinson 1968).  Due to the 
inhibitory action on the high energy utilizing processes, adenosine is described as a 
“retaliatory metabolite” that reduces cellular metabolic demand and restores energy 
levels.  Both adenosine and ATP are ubiquitously found in the extracellular space of most 
organs and tissues in our body and serve as important signaling molecules (Dunwiddie & 
Masino 2001).  In the central nervous system, adenosine generally acts as an inhibitory 
modulator and plays diverse roles in regulating sleep, arousal, neuronal excitability, and 
cerebral blood flow (Dunwiddie & Masino 2001).  ATP, on the other hand, is released by 
injured neurons or activated astrocytes and promotes microglial chemotaxis and 
phagocytosis.  The pro-inflammatory effect of ATP is suppressed by its degradation to 
adenosine, which modulates the inflammatory response by promoting regeneration and 
repair.  Therefore, adenosine serves as a link between cellular metabolism and 
inflammatory signaling (Fredholm et al. 2001, Klotz 2000). 
Adenosine acts as a potent modulator of brain activity by binding to G-protein 
coupled purinergic P1 or adenosine receptors (A1, A2A, A2B, and A3) (Masino et al. 
2009).  Physiological effects of adenosine are primarily mediated by A1 and A2A 
adenosine receptors and are largely considered to be neuroprotective (Boison et al. 2010).  
Adenosine inhibits neuronal excitability by reducing A1 receptor mediated excitatory 
neurotransmitter release while A2A receptors facilitate inhibitory neurotransmitter release 
(Cunha 2005).  Hence, adenosine is widely studied for its anticonvulsant and 
neuroprotective properties (Boison 2005).   
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Formation of adenosine can occur both inside as well as outside the cell and 
distinct cell-specific mechanisms for extracellular elevation of adenosine levels exist 
(Parkinson et al. 2005).  Intracellular ATP levels are tightly controlled however under 
conditions of hypoxia, ischemia, inflammation, nerve stimulation or stress, astrocytes 
release ATP into the extracellular space.  Extracellular ATP is sequentially 
dephosphorylated to adenosine by a cascade of membrane-bound nucleotidases (Figure 
1).  The enzymes responsible for extracellular conversion of ATP to adenosine are CD39 
(ecto-apyrase, converts ATP and ADP into AMP) and CD73 (ecto-5’-nucleotidase, 
converts AMP to adenosine).  Alternatively, neurons release intracellular adenosine 
formed from the breakdown of adenine nucleotides or cleavage of S-
adenosylhomocystein via the nucleoside transporters (Parkinson et al. 2005).  
Extracellular adenosine levels elevated by either pathway result in activation of 
purinergic P1 receptors.  Purinergic signaling by adenosine is terminated by cellular up-
take via nucleoside transporters followed by conversion to AMP by AK (adenosine 
kinase) or catabolism to inosine by intracellular or extracellular membrane-bond ADA 
(adenosine deaminase).  However, due to rapid uptake and metabolism, the metabolic 
half-life of adenosine is very short (Noji et al. 2004).  Thus, therapeutic agents that can 
elevate extracellular adenosine levels for prolonged time intervals can be valuable 
neuroprotective candidates.   
In brain, the innate immune response is initiated by microglia and amplified by 
astrocytes, which through glial communication act to propagate the neuroinflammatory 
response.  It is well known that purinergic signaling is ubiquitous to the brain yet is 
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immerging as a key regulatory mechanism that can disrupt neuroglial communication and 
reduce neuroinflammation (Di Virgilio et al. 2009b).  Both microglia and astrocytes 
possess purinergic P1 and P2 receptors and express enzymes that alter extracellular ATP 
and adenosine levels which modulate purinergic and inflammatory signaling (Di Virgilio 
et al. 2009b).  Because adenosine can influence neuronal activity and attenuate 
neuroinflammation, being able to modulate adenosine levels or the receptors involved in 
purinergic signaling has a broad therapeutic potential (Fredholm et al. 2005a).   
 
Figure 1:  Adenosine metabolism across cell membrane (Parkinson et al. 2005). 
ATP is released into the extracellular space by activated astrocytes or injured neurons.  
Extracellular ATP can directly stimulate purinergic P2X or P2Y receptors, the actions of 
which are terminated by its sequential breakdown into adenosine through membrane-
bound nucleotidases.  The enzyme CD39 converts ATP and ADP into AMP which is 
further broken down into adenosine by CD73.  Adenosine stimulates purinergic P1 or 
adenosine receptors, followed by uptake via bidirectional equilibrative nucleoside 
transporters and subsequent conversion to AMP by the AK enzyme.  Alternatively, 
adenosine can undergo irreversible breakdown into inosine by enzyme ADA.  
Abbreviations: ATP: adenosine triphosphate; ADP: adenosine diphosphate; AMP: 
adenosine monophosphate; ADO: adenosine; INO: inosine; CD39: ecto-apyrase; CD73: 




Lipid synthesis and metabolism 
Lipids are hydrophobic biomolecules that are insoluble in water but soluble in 
organic solvents.  This property of lipids is the basis for their role as structural 
components of cell membranes.  Besides this, their biological functions include energy 
storage, lipid-mediated signal transduction, and post-translational lipid-modification of 
proteins.  The main lipid classes relevant to the study of lipids in brain include 
phospholipids, sphingolipids, cholesterol, and fatty acids that form the main components 
of biomembranes and are important intermediates in lipid signaling.   
De novo synthesis of fatty acids occurs in the cytoplasm from the two carbon 
precursor acetyl-CoA by the activity of three major enzymes: acetyl-CoA carboxylase 
(ACC, rate limiting), fatty acid synthase (FAS), and the Δ-desaturases.  Alternatively, 
some fatty acids are produced as a result of β-oxidation in the mitochondria or directly 
released from the esterified-phospholipid pool by phospholipase A1 and A2 enzymes.  
Thus, the total fatty acid content of a cell at any given time is a total of the esterified and 
the non-esterified fatty acid pools.  Fatty acids either obtained through diet or de novo 
synthesis are incorporated into membrane phospholipids, and the esterified-
polyunsaturated fatty acids serve as a reserve pool for eicosanoid signaling.  Although, 
several studies have studied the incorporation of labeled-acetate into the fatty acid and 
cholesterol pools (Hellman et al. 1954, Howard et al. 1974), it has not been clearly 
demonstrated whether large doses of acetate can stimulate fatty acid synthesis. 
Stimulating lipid synthesis is crucial for the treatment of diseases involving 
myelin degradation or insufficient myelin synthesis, as in multiple sclerosis and Canavan 
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disease, respectively.  In this regard, it has been shown that white matter acetate levels 
are reduced in human brain from multiple sclerosis patient (Li et al. 2013).  On the other 
hand, acetate supplementation increases myelin galactocerebrocide levels in a rat model 
of Canavan disease (Arun et al. 2010b).  Further, aging decreases the poly-unsaturated 
fatty acid content and increases the mono-unsaturated fatty acid content of ethanolamine 
and serineglycerophospholipids (Giusto et al. 2002).  Dietary n-3 polyunsaturated fatty 
acids like docosahexaenoate (DHA) and eicosapentaenoate (EPA) reduce inflammation 
(Ji et al. 2012) and are thought to do so by replacing arachidonate (ARA) at the sn-2 
position of the membrane phospholipids.  Thus, it is important to study the effects of 
acetate supplementation on brain fatty acid synthesis and lipid deposition in 
demyelinating disease models.  
 
Overall hypothesis, approach, and outcomes 
The primary focus of this dissertation was to better understand acetate 
supplementation-induced acetyl-CoA pathways involving purine and lipid metabolism, 
and their contribution towards the anti-inflammatory effects of glyceryl triacetate.  In this 
regard, the TCA cycle is responsible for energy generation and is linked to purine 
metabolism.  Purines and their nucleotides are important signaling molecules that mediate 
inflammation.  Thus we postulated that acetate supplementation reduces inflammation by 
modulating purine metabolism.  To begin to test this hypothesis, we measured the effect 
that short-term acetate supplementation has on brain purine levels using HPLC and found 
that single-dose GTA (6g/kg body weight) increases phosphocreatine and reduces AMP 
levels in normal rat brains (Bhatt et al. 2013).  In parallel experiments, the effect of long-
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term acetate supplementation on brain glycogen levels and mitochondrial biogenesis was 
measured using fluorometric assay, electron microscopy, and cardiolipin analysis.  The 
28 day GTA treatment in normal rats does not alter brain glycogen levels or 
mitochondrial mass (Bhatt et al. 2013).  This study suggested that acetate-induced acetyl-
CoA metabolism stimulates energy production and possibly alters purine metabolism.  
Further, long-term acetate supplementation did not alter brain purine levels in normal rats 
or rats subjected to neuroinflammation.  Since adenosine, a purine nucleoside, is a potent 
modulator of the inflammatory response in the brain (Boison et al. 2010, Masino et al. 
2009), we sought to measure the activity and levels of enzymes involved in adenosine 
metabolism and adenosine receptor levels in a rat model of neuroinflammation.  Using 
Western blot analysis and HPLC based nucleotide assay, we found that both 14 and 28 
day prophylactic acetate supplementation were able to increase CD73 levels and activity 
indicative of greater adenosine production.  Further, the 28 day prophylactic treatment 
reversed LPS-induced increase in AK levels suggesting a reduction in adenosine 
degradation compared to the LPS group.  The LPS group showed an increase in A2A 
receptor levels which were reversed with the 28 day prophylactic treatment.  On the other 
hand, the interventional acetate supplementation strategy elevated CD73 levels but did 
not alter CD73 activity or A2A receptor levels (Smith et al. 2013).   
Since multiple cell types are involved in purinergic signaling and the 
neuroinflammatory response, we designed in vitro experiments using isolated BV2 
microglia and primary astrocyte cultures to determine the contribution of different cell 
types towards alteration of adenosine metabolism.  Using Western blot analysis, in BV2 
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microglia we found that LPS-induced increase in AK and A2A receptor levels were 
similar to that found in vivo however increase in CD73 levels was in contrast to the in 
vivo decrease, all of which were prevented by acetate.  The discrepancy between the in 
vivo and in vitro findings may be due to the differential expression of enzymes and 
receptors by different brain cell types and their relative contribution to the whole brain 
analysis.  In addition to these, we also measured CD39 and ADA enzyme and A1 receptor 
levels where were only ADA levels were increased by LPS but both CD39 and ADA 
levels were reduced to below control levels by acetate in presence of LPS.  Astrocytes, on 
the other hand, showed that acetate treatment in presence of LPS increased CD73 levels 
like in vivo and AK levels unlike our in vivo results.  Further, the A2A levels unlike in 
vivo results remained unaltered with both LPS and acetate treatment.  Additionally, we 
also measured CD39, ADA and A1 receptor levels and found that LPS –induced increase 
in CD39 levels was not altered by acetate.  Moreover, the ADA levels remained unaltered 
by both LPS and acetate plus LPS while A1 receptors were below the level of detection.  
Acetate-induced increase in astrocytic AK levels may be a compensatory mechanism to 
replenish cellular nucleotide levels released from astrocytes and metabolized by CD39 
and CD73. 
Therefore, we took an alternatively approach to determine the effect of acetate in 
the presence and absence of LPS on extracellular adenosine levels in isolated BV2 
microglia and astrocyte cultures using HPLC with fluorescence detection.  We did not 
find any changes in extracellular levels of adenosine in microglia and astrocyte cultures.  
The lack of elevation in extracellular adenosine levels may be due to rapid adenosine 
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turnover (Noji et al. 2004).  Nonetheless, it is possible that purinergic signaling is 
dependent upon paracrine communication between different cell types including 
microglia, astrocyte, and neurons, and that may have affected the extracellular adenosine 
measurements.  Therefore, diverse co-culture paradigms including mixed glial cultures 
co-cultured in presence and absence of neurons, or organotypic slice cultures may be a 
more suitable way to better characterize the effects of acetate on purinergic signaling.  
Further, pretreatment of cultures with adenosine uptake and degradation inhibitors can 
greatly enhance the chances of detecting changes in extracellular adenosine levels. 
Lastly, we investigated the effect of acetate in the presence and absence of LPS 
on fatty acid, phospholipid, and cholesterol content of BV2 microglia in order to 
demonstrate whether acetate-induced acetyl-CoA can stimulate lipid synthesis.  Cellular 
esterified and non-esterified fatty acids were converted into their methyl esters and 
analyzed using gas chromatography.  Total phosphorus content of individual 
phospholipid classes was measured using a phosphorus assay and cholesterol levels were 
measured using a colorimetric assay.  In this proof-of-principle experiment, we found that 
acetate showed marked increases in BV2 cell fatty acid content, modest increase in 
cholesterol content without altering phospholipid levels (Bhatt & Rosenberger 2013).  
These data support the hypothesis that acetate can stimulate fatty acid synthesis in these 
cultures but future studies are required to determine if the changes in fatty acid content 






Standards:  Nucleotide standards [adenosine, ATP, ADP, AMP, α, β-methylene 
adenosine diphosphate (AMPCP), NAD, GTP], and phosphagen standards 
[phosphocreatine (PCr) and creatine (Cr)] were purchased from Sigma–Aldrich (St. 
Louis, MO).  
14
C-labeled ATP, ADP, and AMP were obtained from American 
Radiolabeled Chemicals, Inc. (St. Louis, MO).  Creatinine standard and bovine serum 
albumin protein standard (fraction V, fatty acid free) were from MP Biomedicals, LLC 
(Solon, OH).  The standard 1, N
6
-ethenoadenosine was from Axxora, LLC (San Diego, 
CA).  Fatty acid methyl ester standards, phospholipid standards, and cholesterol were 
from NuCheckPrep, (Elysian, MN).  Western blotting markers, Prestained SDS-PAGE 
Standards (#161-0318) and Precision Plus Protein™ WesternC™ Standards (#161-0376) 
were purchased from Bio-Rad Laboratories (Hercules, CA). 
Chemicals:  Sodium acetate (99%), trichlorofluromethane (Freon), 
chloroacetaldehyde (50%), trioctylamine, glucose, hexokinase, myokinase, glyceryl 
triacetate (GTA, 99%), trioctylamine, bacterial lipopolysaccharide (LPS, Escherichia 
Coli 055:B5), 6-(p-Toluidino)-2-naphthalenesulfonic acid sodium salt (TNS), ferric 
chloride heptahydrate, and gelatin were purchased from Sigma–Aldrich (St. Louis, MO).  
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The ion-pair reagent tetrabutylammonium phosphate (TBAP) was purchased from 
Mallinckrodt Baker, Inc. (Phillipsburg, NJ).  HPLC grade acetonitrile, methanol, 2-
propanol, chloroform, mono-basic potassium phosphate (KH2PO4), perchloric acid, 
phosphoric acid, sulfuric acid, acetone, sodium hydroxide, ammonium hydroxide, tris-
base, sodium dodecyl sulfate (SDS), and bovine serum albumin were obtained from EMD 
Chemicals Inc. (Gibbstown, NJ).  Poly-L-lysine was obtained from MP Biomedicals, 
LLC (Solon, OH).  Glacial acetic acid, n-hexane, toluene, and all cell culture supplies 
were acquired through VWR International, LLC (Batavia, IL).  GC grade anhydrous 
methanol was from Macron™ Chemicals (Charlotte, NC).  Glutaraldehyde, 
paraformaldehyde, osmium tetraoxide, uranyl acetate, lead citrate, embed-812 (Epon-812 
substitute) WPE #154.3; araldite-502 (modified bisphenol A epoxy); BEEM embedding 
capsule size#3; cresyl fast violet C.I.#51180, pre-cleaned Gold Seal micro-slides and 
formvar carbon support film specimen 2 x 1 mm slot grids were purchased from Electron 
Microscopy Science (Hatfield, PA).  All Western blot supplies including acrylamide, bis-
N,N’-methylene-Bis-acrylamide, N,N,N’,N’-tetramethylene-diamine (TEMED), 
ammonium persulfate, 12 and 24 well Criterion Empty Cassettes (#345-9901 and #345-
9903) were obtained from Bio-Rad Laboratories (Hercules, CA).  The complete EDTA-
free protease inhibitor cocktail tablets were from Roche Applied Science (Indianapolis, 
IN). 
Antibodies:  Primary antibodies for CD73 (1:1000, sc-14684), CD39 (1:1000, sc-
18771), A2AR (1:1000, sc-32261), A1R (1:1000, sc-7500), ADK (1:1000, sc-23360), 
ADA (1:1000, sc-7451), a-tubulin (1:4000, sc-8035), H3 (1:1000, sc-8654), and 
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acetylated- histone H4 (S1/K5/8/12, 1:1000, sc-34263) were obtained from Santa Cruz 
Biotech. Inc. (Santa Cruz, CA).  Antibodies against acetylated-histone H3 (K9, 1:10,000, 
07-352), and histone H4 (1:8000, 04-858) were purchased from Millipore (Billerica, 
MA).  The HRP-conjugated secondary antibodies: donkey anti-goat IgG (1:10,000, sc-
2020), goat anti-mouse IgM (1:10,000, sc-2064), goat anti-mouse IgG (1:10,000, sc-
2005) were purchased from Santa Cruz Biotech. Inc. (Santa Cruz, CA).  The goat anti-




Male Sprague-Dawley rats were purchased from Harlan Laboratories 
(Indianapolis, IN) and experiments were performed following the Guide for the Care and 
Use of Laboratory Animals (NIH publication number 80–23) as approved by the 
University of North Dakota Animal Care and Use Committee.  All rats were allowed to 
acclimate for seven days prior to inclusion in the study, maintained on standard 
laboratory chow diet, and provided water ad libitum.  For studying the effect of single-
dose acetate supplementation on nucleotide and phosphagen levels, rats weighing 150-
250 g were given GTA (6 g/kg body weight) by oral gavage while control rats received 6 
g/kg body weight water.  Rats were anaesthetized with sodium pentobarbital (50 mg/kg, 
i.v.) and subjected to head-focused microwave (6 kW, 2s) irradiation at 2, and 4 h post-
treatment to immediately stop metabolism.  Microwave-fixed brains were flash frozen, 
pulverized in liquid nitrogen, and then stored at -80 °C until use.  Parallel sets of rats 
(100-250 g) used to quantify the effects of long-term acetate supplementation on brain 
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cardiolipin content, neuronal mitochondria, and nucleotide and phosphagen levels 
received a daily dose of GTA or water (6 g/kg body weight) for 28 days and were 
euthanized 1 h after the last treatment.  The 28 day treatment regimen for the 
mitochondrial number, and cardiolipin content experiments is based on the 24.4 day half-
life of brain mitochondria (Menzies & Gold 1971) and previous results demonstrating a 
therapeutic effect of GTA in a rat model of neuroinflammation (Reisenauer et al. 2011).  
Rats used for cardiolipin, nucleotide, and phosphagen measurements were euthanized by 
head-focused microwave irradiation as described above.  Rats used for measuring 
neuronal mitochondrial number were anaesthetized using isoflurane (Butler Animal 
Health Supply, Dublin, OH) and euthanized by cardiac perfusion with heparinized saline 
followed by a mixture of 4 % paraformaldehyde and 2 % glutaraldehyde in 0.1 M 
phosphate buffer.  Whole brain was removed and post-fixed in the same mixture for 48 h 
at 4 ºC after which they were transferred to 0.1 M phosphate buffered saline (PBS, pH 
7.4) and stored at 4 ºC until use. 
 
Rat Model of Neuroinflammation 
To determine if chronic inflammation alters the long-term effect of acetate 
supplementation on brain nucleotides, phosphagens, adenosine metabolizing enzymes 
and receptors, rats were subjected to LPS-induced neuroinflammation.  Male Sprague 
Dawley rats weighing between 160 and 180 g (Charles River Laboratories, Portage, MI, 
USA) were anaesthetized with 3% isoflurane (Butler Animal Health Supply, Dublin, OH, 
USA) by continuous inhalation for stereotactic surgery as described (Hauss-Wegrzyniak 
et al. 1998a, Hauss-Wegrzyniak et al. 1998b).  A cannula (Model 3280PM, Plastics One, 
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Roanoke, VA, USA) connected to a subcutaneous osmotic mini-pump (ALZET
®
, Model 
2004, DURECT Corporation, Cupertino, CA) was implanted into the fourth ventricle of 
the rat brain.  The osmotic pump continuously infused a solution of LPS [5.0 ng/h, 
dissolved in artificial cerebral spinal fluid (aCSF)] or aCSF (Harvard Apparatus, 
Holliston, MA, USA) at a steady rate of 0.25 µL/h for a period of 28 days.  During this 
period rats were treated daily by oral gastric gavage with either 6 g/kg dose of GTA or 
water.  The rats for nucleotide and phosphagen analysis were divided into four different 
groups: group one (n = 5) received an aCSF infusion and treated daily with water for 28 
days (aCSF + H2O), group two (n = 4) received an aCSF infusion and daily treatment 
with GTA for 28 days (aCSF + GTA), group three (n = 6) received a LPS infusion and 
daily treatment with water for 28 days (LPS + H2O) and group four (n = 6) received a 
LPS infusion and daily treatment with GTA for 28 days (LPS + GTA).  After the 28
th
 day 
treatment, rats were anaesthetized, their brains microwave-fixed, pulverized in liquid 
nitrogen, and stored at -80 °C as stated above. 
The rats used for in vivo adenosine metabolizing enzymes and receptor level 
studies were divided into three separate experiments; a 14, and 28 day prophylactic 
treatment study, and a 28 day interventional treatment study.  During the 14 and 28 day 
prophylactic treatment studies, rats were treated daily with water or glyceryl triacetate 
(GTA) at a dose of 6 g/kg by oral gavage.  In the 28 day interventional study, rats did not 
begin receiving daily doses of either water or GTA until 14 days after the start of the LPS 
infusion, the time at which neuroglia activation, based on morphological differences, is 
significantly elevated above controls (Hauss-Wegrzyniak et al. 1998a).  Rats used for 
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Western blot analysis were anesthetized with isoflurane, euthanized by decapitation, 
brains removed and flash frozen in liquid nitrogen.  The post-mortem interval for the 
samples did not exceed 1.5 min.  Brains samples used for Western blot analysis were 
stored at -80 °C until use.   
 
Nucleotide and Phosphagen Extraction from Rat Brain 
Nucleotides and phosphagens were extracted using a modified tissue extraction 
protocol as described (Hammer et al. 1988).  In brief, 10–50 mg pulverized brain sample 
was homogenized in ice cold 0.6 M perchloric acid in a pre-cooled Tenbroeck glass 
homogenizer then transferred to a micro-centrifuge tube.  The homogenizer was then 
washed twice with 0.6 M perchloric acid and the combined homogenates were 
centrifuged at 13,000 x g at 25 
o
C for 2 min.  The supernatant was neutralized with ice 
cold Freon/trioctylamine (4:1, by Vol.) by vortex mixing for 30 sec and the pellet was 
saved for protein determination.  The neutralized extract was centrifuged at 13,000 x g 
for 2 min to induce phase separation and the upper aqueous layer was collected and 
stored at 4 °C until analysis.  Phosphagens were analyzed within 3 h of extraction and 
nucleotides were analyzed within 24 h using high performance liquid chromatography 
(HPLC) as outlined below. 
 
Preparation of Nucleotide and Phosphagen Standards 
All standard stock solutions were prepared by dissolving 10–25 mg of a pure 
nucleotide in 1–1.5 mL of deionized water or 100 mM KH2PO4 buffer (pH 7.5) and 
stored at -20 °C until use.  Standard solutions were diluted 1000-fold and the absorbance 
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was recorded at 259 nm for adenine nucleotides, 253 nm for GTP, and 275 nm for 1, N
6
- 
ethenoadenosine.  The molar concentration of the stock standards was calculated using 
the molar extinction coefficients.  Stock standards were further diluted in deionized water 
or 100 mM KH2PO4 buffer (pH 7.5) to prepare individual (1 or 2 mM) and mixed (50 
µM) working nucleotide standards.  All calibration procedures were performed using 
freshly made stock standards or frozen 1–2 mM aliquots.  The working standards were 
stored at 4 °C for no more than one month prior to use.  The purity of the adenine 
nucleotide working standards was determined using HPLC with UV detection described 
below and are listed in Table 1.  Stock phosphagen standards were freshly prepared (10 
mM) on weight bases in deionized water and were diluted appropriately to obtain 
working standards for generating standard curves. 
Table 1: Percentage purity of individual and mixed stock nucleotide standards 
 Percentage nucleotide content of standards 
 Adenosine AMP ADP ATP Mixture 
Adenosine 100.0 ± 0.0 3.5 ± 0.4 - - 103.5 ± 0.4 
AMP - 96.5 ± 0.4 6.6 ± 0.8 - 103.1 ± 0.6 
ADP - - 93.4 ± 0.8 2.5 ± 0.3 95.9 ± 1.1 
ATP - - - 97.5 ± 0.3 97.5 ± 0.3 
Values represent means ± standard deviation (SD, n = 3) expressed as percentage of total 
peak area 
Quantification of Brain Nucleotides 
Nucleotide analysis from rat brain samples was performed using HPLC with UV 
detection as described (Hammer et al. 1988) with slight modifications.  The separation 
was performed on an ISCO HPLC system with an in-line UV detector (model V
4
) and a 
Waters Sunfire
TM
 ODS column (5 µm, 250 x 4.6 mm, Milford, MA) equipped with a C18 
SecurityGuard cartridge (Torrance, CA).  Column temperature was maintained at 40 °C.  
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HPLC system was controlled and data analysis was performed using Clarity advanced 
chromatography software (Ver. 2.6, DataApex, Prague, Czech Republic).  The mobile 
phase consisted of buffer A, 30 mM KH2PO4 + 7.5 mM TBAP, pH 5.45; and buffer B, 
acetonitrile/30 mM KH2PO4 (1:1, by Vol.) + 7.5 mM TBAP, pH 7.0 (adjusted before 
addition of the organic phase).  Buffers were filtered using a 0.45-µm Supor-450 
membrane filter (Pall Corporation, Ann Arbor, MI) prior to addition of the ion-pairing 
reagent (TBAP).  The 40 min gradient elution program consisted of 10% buffer B 
initially maintained for 0.5 min and then increased to 25% over a period of 8.5 min and 
held constant for 2 min.  The gradient was then increased to 50% buffer B over 4 min 
followed by a gradient to 60% over 19 min.  At 34 min the proportion of buffer B was 
decreased to 10% over a 4 min period, held constant for 2 min, and the column was 
allowed to equilibrate for 20 min before injection of the next sample.  The flow rate was 
held constant at 1 mL/min throughout the separation and the nucleotide detection was 
performed at 260 nm.  The peaks were identified by comparison of sample retention 
times to known standards.  Calibration curves generated based on standard peak area 
were used to quantify sample nucleotide levels.  The results obtained are expressed as 
nmoles of nucleotide per mg of protein. 
 
Quantification of Brain Phosphagens 
Phosphagens analysis was performed as described (Dunnett et al. 1991) using the 
HPLC and UV detection system described above with a modified solvent and gradient 
system, and a Waters Spherisorb
®
 ODS2 column (5 µm, 250 x 4.6 mm Milford, MA).  
The mobile phase consisted of buffer A, 14.7 mM KH2PO4 + 2.3 mM TBAP, pH 3; and 
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buffer B, acetonitrile/14.7 mM KH2PO4 (1:1, by Vol.) + 2.3 mM TBAP, pH 6.5 (prepared 
in the same manner as described for nucleotide analysis).  The 35 min elution gradient 
was started at 100% buffer A for the first 5 min followed by a gradient increase in buffer 
B to 10% over a period of 6 min.  At 11 min, the composition of buffer B was increased 
to 50% over 5 min and held constant for 5 min.  The gradient was returned to 100% 
buffer A over 5 min and held constant for 9 min.  The column was allowed to equilibrate 
for 20 min prior to the next run and the flow rate was held constant at 1 mL/min 
throughout the separation.  Phosphagen detection was performed at 210 nm and the peaks 
were quantified using external calibration standards.  The results are expressed as nmoles 
of phosphagen per mg protein. 
Certain rat brain samples for nucleotide and phosphagen analysis were analyzed 
on a System Gold
®
 125 Solvent Module (Beckman Coulter, Inc., Fullerton, CA) 
equipped with a System Gold
®
 508 autosampler and an in-line System Gold
®
 168 UV 
detector (Beckman Coulter, Inc., Fullerton, CA).  The column and separation parameters 
were same as mentioned above for nucleotide and phosphagen analysis. 
 
Glycogen Analysis 
Whole brain glycogen was measured in microwave-fixed pulverized brain 
samples as per the method described by (Cruz & Dienel 2002) with modifications.  
Approximately, 50 mg brain powder was homogenized in phosphate buffered saline (pH 
7.0) followed by glucose solubilization and glycogen precipitation with ethanol (65% of 
total Vol.).  The samples were vortex mixed and centrifuged at 13,000 x g at 4 
o
C for 10 
min.  The supernatant containing endogenous glucose was discarded and the pellet was 
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homogenized in 1.5 mL of 0.03 M hydrochloric acid.  Samples were than heated at 90 °C 
for 45 min followed by centrifugation at 13,000 x g at 4 
o
C for 10 min.  A 10 µL aliquot 
of the supernatant containing glycogen was incubated with amyloglucosidase enzyme to 
release glucosyl units which were quantified using a commercial fluorometric kit 
(Cayman Chemical Company, Ann Arbor, MI).  Basal glucose levels obtained from 
samples not incubated with the enzyme served as background and were subtracted from 
total glucosyl units released from glycogen.  Brain glycogen levels are expressed as µmol 
of glucosyl units released per gram brain. 
 
Cardiolipin Analysis 
Microwave-fixed and pulverized rat brain samples were extracted in n-hexane: 2-
propanol (3:2, by Vol.) using a Tenbroeck homogenizer (Hara & Radin 1978).  Tissue 
extracts and cardiolipin standards, dissolved in chloroform, were isolated on 20 cm x 20 
cm TLC Silica gel 60 plates (EMD Chemicals Inc., Gibbstown, NJ) using a two-solvent 
system.  Solvent A was chloroform/methanol/acetic acid/formic acid/water (70:30:12:4:2, 
by Vol.), and Solvent B was n-hexane/di-isopropyl ether/acetic acid (63:35:2, by Vol.).  
Two TLC chambers were equilibrated with the solvents for at least 1 h before separation.  
Samples and standard were spotted on the plate, dried for 5 min at 85 °C then placed into 
the TLC chamber containing solvent A and eluted for 10 cm.  The TLC plate was air 
dried for 15 min then eluted to the top of the plate with solvent B.  Bands were visualized 
using either iodine vapors (phosphorus assay) or with a TNS solution (50 mM in 25 mM 
Tris buffer, pH 7.4) using UV light (fatty acid analysis).  Cardiolipin mass was measured 
using a phosphorus assay as described (Rouser et al. 1966) using KH2PO4 dissolved in 
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deionized distilled water (0.125–4.0 mM) as standards.  The fatty acid composition of 
cardiolipin was measured by gas liquid chromatography as described (Long et al. 2010).  
Fatty acid standards were used to identify and quantify the fatty acid components in the 
samples based on their retention times and concentration factors, respectively.  Brain 
cardiolipin levels are expressed as nmoles of phosphorus per mg protein and the fatty 
acid content of cardiolipin is expressed as nmoles of fatty acid per mg protein and mole 
percentage of total fatty acid content.   
 
Electron Microscopy 
Brain tissue was embedded in a plastic mold using 12% gelatin and egg yolk (1:2, 
by Vol.) then post-fixed in 4% paraformaldehyde/2% glutaraldehyde for 48 h at 4 °C.  
Transverse 40 µm sections were isolated from the CA3 region of the hippocampus using 
a Vibratome (Bannockburn, IL), and placed in PBS (pH 7.4) at 4 °C.  The sections were 
incubated in 2% osmium tetraoxide in 0.1M PBS at 37 °C for 45 min, dehydrated with 
increasing concentrations of ethanol/propylene oxide, infiltrated overnight in 
Epon/Araldite embedding medium (Ted Pella), flat mounted between silanized glass 
slides, then polymerized at 60 °C for 72 h.  The Vibratome sections embedded in 
Epon/Araldite medium were visualized under light microscope to morphologically 
identify the stratum pyramidale cell bodies in the CA3 region of the hippocampus and 
were glued to an Epon/Araldite bullet for ultrathin sectioning.  Ultrathin sections (90–120 
nm) were serial mounted on copper (2 x 1 mm) formvar/carbon stabilized slot grids.  The 
slot grids were stained in a Leica EM AC20 autostainer (Richmond, IL) using 0.5% 
uranyl acetate for 30 min followed by 7 min in 3% lead citrate with intermittent water 
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rinses.  Sections were examined at 60 kV in a Hitachi H-7500 transmission electron 
microscope (Pleasanton, CA).  Neurons were identified based on size, morphology, and 
presence of large nucleoli and their identity was confirmed by presence of synapses and 
absence of heterochromatin.  Images were collected at 4,000 X and 20,000 X 
magnification and digitized with an Epson Perfection V750 PRO scanner (Long Beach, 
CA).  Total cytosolic area and mitochondrial number from at least twelve CA3 neurons 
per animal were quantified.  Approximately 10–20 micrographs covering the complete 
neuronal soma were integrated with minimum overlap using MCID
TM
 Analysis 7.0 
software (InterFocus Imaging Ltd, UK).  All micrographs were coded and analyzed by a 
third party blind to the experimental conditions.  The results are expressed as total 




Rat Brain Extraction for Ecto-5’-nucleotidase Activity 
Brains were placed on ice, dissected at the middle carotid artery, and the anterior 
portion was placed in a tube containing 3 mL of ice cold extraction buffer (50 mM Tris 
buffer (pH 7.4) containing 150 mM sodium chloride, 1 mM EGTA, 1 mM sodium 
orthovanadate, 5 mM zinc chloride, 100 mM sodium fluoride, 1 mM PMSF, one 
complete, EDTA-free tablet (Roche Applied Science, Indianapolis, IN) per 50 mL, and 
0.1% Igepal CA-630).  The sample was allowed to sit on ice for 10 min then 
homogenized using probe sonication until no solid was evident.  Homogenized samples 
were centrifuged at 4 °C for 20 min at 4,500 x g and the cytosolic portion was aliquoted 




Ecto-5’-nucleotidase Activity Assay 
Sample brain extracts were diluted in ice cold assay buffer [50 mM Tris buffer 
(pH 7.4 at 37 °C] containing 20 mM β-glycerophosphate, and 20µM erythro-9-(2-
hydroxy-3-nonyl) adenine) to a protein concentration of 3.33 µg/µL.  Each sample (500 
µg protein) was assayed in duplicate, with one assay containing 400 µM α, β-methylene 
adenosine 5’-diphosphate in the buffer, as a control to inhibit the activity of CD73.  
Samples were pre-incubated at 37 °C for 10 min and the assay was started by adding 1 
mM AMP and incubating for 30 min at 37 °C.  The reaction was stopped with 3 M 
perchloric acid and placed on ice before being centrifuged at 18,100 x g for 5 min at 4 °C.  
The adenosine formed by CD73 was then converted into its fluorescent derivative and 
quantified using HPLC with fluorescence detection as described below (Bhatt et al. 
2012).  Adenosine levels from the control reaction were subtracted from the experimental 
reaction to calculate CD73 activity in units of nmol adenosine/mg protein/min 
 
Cell culture 
Primary astrocyte culture:  Primary cortical astrocyte cultures were prepared from 
3-4 day old Sprague-Dawley rat pups as described (McCarthy & de Vellis 1980) in 
accordance with the Guide for the Care and Use of Laboratory Animals (NIH publication 
number 80-23) as approved by the University of North Dakota animal care and use 





free Hanks balanced salt solution (CMF-HBSS, Mediatech Inc, 
Manassas, VA).  After removing the meninges, cerebral hemispheres were separated and 
the cerebellum and white matter were dissected out to isolate the cortical region.  Pooled 
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cortices from 3–4 rat pups were rinsed with CMF-HBSS, minced and transferred to a 
polypropylene tube.  To dissociate the cells, the samples were triturated using a glass 
pipette and incubated at 37 °C on a shaking water bath for 10 min.  The cell suspension 
was then centrifuged at 360 x g for 5 min and the cells were re-suspended in DMEM/F12 
media (Mediatech Inc, Manassas, VA) containing 15% fetal bovine serum (FBS, PAA 
Laboratories Inc, Dartmouth, MA).  The cell pellet was triturated into solution then plated 
in the ratio of 0.5 brains per 25 cm
2
 flask (pre-coated with poly-L-lysine) and were 
allowed to grow for 7 days in DMEM/F12/10% FBS media supplemented with penicillin 
(100 IU/mL), streptomycin (100 µg/mL), amphotericin B (2.5 µg/mL) and HEPES (10 
mM) in a humidified incubator with 5 % CO2 (Binder, Tuttlingen, Germany).  The cell 
culture media was replaced every alternate day throughout the study.  On day 8, cells 
were transferred to a shaking incubator at 37 °C for 24 h under air-restricted conditions to 
remove oligodendrocytes and microglia.  Astrocyte-enriched cell cultures were allowed 
to grow for another 4 days and then on day 12 the astrocyte cell cultures were divided 
onto 100 x 20 mm poly-L-lysine coated culture dishes or 6 well plates using trypsin (BD 
and Company, Sparks, MD) at a density of 1.0 x 10
6
 cells/dish or 5.0 x 10
5
 cells/well, 
respectively.  The enrichment of astrocytes was determined to be greater than 95 % by 
GFAP immuno-fluorescence staining as described (Weinstein 2001).  At approximately 
90% confluence, media was removed and washed three times with CMF-HBSS followed 
by appropriate treatment in DMEM/F12 media without serum. 
Culturing BV2 microglial cell line:  The immortalized murine BV2 microglial cell 
line (Bocchini et al. 1992) was obtained from Dr. Colin K. Combs (University of North 
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Dakota, Grand Forks, ND).  The cells were cryo preserved under liquid nitrogen in 
DMEM/F12 media containing 20% FBS and 10% dimethyl sulfoxide (DMSO).  Frozen 
cultures were thawed, washed with DMEM/F12 media containing 10% FBS to remove 
DMSO and cultured in DMEM/F12/10% FBS medium in 100 x 20 mm dishes.  BV2 
cells at approximately 27
th
 passage were plated in 6 well-plates at a density of 5.0 x 10
5
 
cells/well and allowed to reach 80–90% confluence before experimental treatment. 
Cell culture treatment:  A cell viability assay [lactate dehydrogenase (LDH) assay 
as describe below] was conducted with different sodium acetate (NaAc) and sodium 
chloride (NaCl) concentrations (8, 12, 16, 32 mM) in primary astrocyte cultures to detect 
the highest tolerable dose of acetate.  No significant cell death compared to the normal 
serum control was observed with 8 and 12 mM NaAc and NaCl.  However, at 16 and 32 
mM significant LDH release was observed with both NaAc and NaCl demonstrating that 
the increase in cell death was due to increase in osmolarity of the medium.  Further, the 
concentrations (8 and 12 mM) that were devoid of significant cell death bracket the in 
vivo levels of brain acetate (8.5 µmol/g brain ~10.6 mM) achieved with a comparable 
dose of GTA (5.8 g/kg body weight) in mice (Mathew et al. 2005).  Therefore, for our in 
vitro experiments we selected a dose of 10 mM NaAc to mimic in vivo acetate 
supplementation.  Equimolar NaCl served as a control to account for the osmolarity 
changes in the culture medium with treatment.  BV2 cells or primary astrocytes grown in 
6 well plates or 100 x 20 mm dishes (80–90% confluent) were either serum starved for 1–
24 h or directly treated with NaAc/NaCl (5–10 mM) in presence or absence of LPS 
(6.25–1000 ng/mL) for 0.25–48 h.  For cellular nucleotide, phosphagen, adenosine 
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metabolizing enzymes and receptor analysis cultures were treated with 10 mM NaAc 
with/without LPS (1000 ng/mL) along with the NaCl control.  Cultures used for 
extracellular nucleotide analysis were treated with NaCl/NaAc in the presence and 
absence of LPS (1000 ng/mL) in HBSS instead of the DMEM/F12 medium.  For lipid 
analysis, BV2 cells were not serum starved and were treated with 1, 5, and 10 mM NaAc 
with/without LPS (6.25 ng/mL) for 2 h. 
 
Lactate Dehydrogenase Assay for Cell Death Determination 
Cellular release of lactate dehydrogenase (LDH) enzyme was used to measure cell 
viability by using a commercial nonradioactive colorimetric micro plate assay kit 
(Clontech Laboratories Inc., Mountain View, CA), according to the manufacturer’s 
guidelines.  Sample and LDH standard absorbance values were measured at 490 nm with 
630 nm as the reference wavelength.   
 
Nucleotide Extraction from Cell Cultures 
Following treatment, culture dishes or plates were flash frozen by rapid 
immersion in liquid nitrogen.  The cells were stored at -80 °C prior to nucleotide analysis.  
Frozen cells were scrapped off culture dishes on dry ice and were transferred to a micro-
centrifuge tube pre-chilled in liquid nitrogen.  The frozen cells were homogenized using a 
Polytron
®
 PT1200E homogenizer (Kinematica Inc, Bohemia, NY) in 500 µL ice cold 0.6 
M perchloric acid to extract the nucleotides.  The homogenate was centrifuged at 13,000 
x g for 2 min at 4 °C.  The supernatant was collected and neutralized with 1 mL ice cold 
freon/trioctylamine (4:1, by Vol.).  The pellet was saved for protein determination.  The 
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neutralized nucleotide extract was vortex mixed for 30 sec then centrifuged at 13,000 x g 
for 2 min to induce phase separation.  The upper aqueous layer was collected and stored 
at 4 °C until derivatization for not more than 24 h.  For extracellular nucleotides, HBSS 
buffer incubated with the cells was collected after several time-points and was directly 
mixed with ice-cold perchloric acid (final concentration 0.6 M) to precipitate dissolved 
proteins.  The extract was centrifuged at 13,000 x g at 25 
o
C for 2 min and immediately 
neutralized with ice cold freon/trioctylamine (4:1, by Vol.).  The adenine nucleotides 
were derivatized and analyzed using HPLC with fluorescence detection as describe 
below. 
 
Quantification of Cell Culture Nucleotides 
Adenine nucleotides from the cellular nucleotide extracts or extracellular medium 
were converted into respective fluorescent 1, N
6
-etheno derivatives and quantified using 
an ion-pairing HPLC method with fluorescence detection.  Briefly,  a 50 µL aliquot of the 
nucleotide extract was mixed with 150 µL freshly prepared mix of chloroacetaldehyde 
(7.8 M) and 1 M acetate buffer (pH 4.5) [11.2: 138.8, by Vol.] in a 13 mm capped glass 
tube.  Tubes were vortex mixed, centrifuged at 450 x g for 2 min at 22 °C, and then 
heated to 60 °C for 60 min in a Techne DRI-Block DB-3A (Techne, Cambridge, UK).  
After the reaction, the tubes were immediately placed at 4 °C to stop the reaction, 
centrifuged at 450 x g for 2 min at 22 °C and then diluted with water to 1:6 for AMP and 
adenosine while a 1:80 dilution was used for ATP and ADP analysis.  A 100 µL aliquot 
of this solution was placed in a microvial and 50 µL of the derivatized sample was 
injected on the HPLC system described below for analysis.   
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Etheno-derivatized adenine nucleotides from cell culture samples were analyzed 
using a System Gold
®
 125 Solvent Module (Beckman Coulter, Inc., Fullerton, CA) 
equipped with a System Gold
®
 508 autosampler and an in-line Jasco FP-2020 
fluorescence detector (Jasco Corporation, Tokyo, Japan).  Separation was performed on a 
Waters Sunfire
TM 
ODS column (5 µm, 250 x 4.6 mm, Milford, MA) equipped with a C18 
SecurityGuard cartridge (Phenomenex, Torrance, CA) at 22
o
 C.  HPLC system was 
controlled and data analysis was performed using the 32 Karat™ software (Ver. 7.0, 
build 1048, Beckman Coulter Inc., Fullerton, CA).  The mobile phase consisted of buffer 
A, 30 mM KH2PO4 + 0.8 mM TBAP, pH 5.45; and buffer B, acetonitrile/30 mM KH2PO4 
(1:1, by Vol.) + 0.8mM TBAP, pH 7.0.  The pH of buffer B was adjusted to 7.0 prior to 
the addition of acetonitrile.  All buffers were filtered using a 0.45-µm Supor-450 
membrane filter (Pall Corporation, Ann Arbor, MI) prior to addition of the ion-pairing 
reagent (TBAP).   
The etheno-adenine nucleotides were eluted using the following gradient.  The 
initial buffer B concentration was maintained at 10 % for 0.5 min, increased to 20% over 
a period of 2.5 min, and then held constant for 4 min.  At 7.0 min the concentration of 
solvent B was increased to 50% over a 4 min period and then held constant for 10 min.  
At 21 min the proportion of buffer B was decreased back to the starting concentration of 
10% over a 4 min period and then held constant for 5 min until the end of the run.  The 
re-equilibration time between samples and the flow rate was held constant at 20 min and 
1 mL/min, respectively.  The quantification of the etheno-adenine nucleotides was 
performed using an excitation wavelength of 280 nm with an output emission wavelength 
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set at 410 nm.  The identity of etheno-adenine nucleotides were determined by comparing 
retention times to known nucleotide standards and were further confirmed by enzymatic 
peak shift analysis.  Calibration curves were generated using a series of mixed nucleotide 
standards (0.15–20.0 pmol) that were derivatized similar to cellular nucleotide extracts.  
Linear regression of standard peak areas Vs nucleotide amount was used to quantify 
sample nucleotide content, which was normalized to total cellular protein and expressed 
as pmol or nmol of nucleotide per mg protein. 
 
Western Blot Analysis 
For whole brain protein samples, Western blot analysis was performed on CD73 
activity protein extracts.  However, for cell culture proteins, cells were washed with PBS, 
lysed in radio immuno precipitation assay buffer (50 mM Tris, pH7.5, 150 mM NaCl, 
0.1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 1 mM EDTA, 1mM EGTA, 
10 mM sodium fluoride, 1mM sodium orthovanadate, 2.5 mM sodium pyrophosphate 
containing 1 Roche protease inhibitor cocktail per 50 mL buffer), sonicated for 1 min, 
and centrifuged to collect the soluble protein supernatant.  Extracts were stored at -80 °C 
until used.  Equal amount of protein across samples (10–50 µg/well) was denatured in 2x 
Laemmli sample buffer and separated using sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (15%) at 80–100 V for 2 h at room temperature.  Proteins were 
transferred to nitrocellulose membranes on ice at 100 V for 1.5 h and blocked with 5% 
milk in tris-buffered saline (20 mM Tris base and 150 mM NaCl, pH 7.5) containing 
0.05% Tween (TBS-T).  Blots were incubated overnight with primary antibodies 
(1:1000) at 4 °C, washed four times in TBS-T and incubated with secondary antibodies 
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(1-10,000) at room temperature.  Protein bands were visualized with a SuperSignal® 
West Pico and/or Femto enhanced chemiluminescent substrate (Pierce, Rockford, IL) 
using a UVP Bioimaging System (Upland, CA).  Image capturing and analysis was 
performed with LabWorks
TM
 imaging software (version 4.5.0, UVP Inc., Upland, CA) 
and VisionWorksLS analysis software (version 6.3.1, UVP LLC, Upland, CA), 
respectively.  Optical density of α-tubulin was used for normalization of proteins except 
acetylated H3 and H4 which were normalized to total H3 or H4 histones.  All Western 
blot data are expressed as fold change over controls.  
 
Lipid Extraction from BV2 Cell Culture 
Lipids from cultures treated with NaCl or NaAc in presence or absence of LPS 
were extracted by the n-hexane: 2-propanol (3:2, by Vol.) method (Hara & Radin 1978).  
BV2 cells grown in 6 well plates were washed in PBS and immediately frozen by placing 
the plate on liquid nitrogen to minimize fatty acid hydrolysis due to acylhydrolase 
activation.  Cells were scrapped on dry ice after addition of 2 mL 2-propanol to the 
frozen plates and the suspension was transferred to a 16 mm tube.  The wells were 
washed with 2 mL 2-propanol and was combined with the initial suspension.  The 
suspension was vortex mixed after addition of 6 mL n-hexane (3:2, n-hexane: 2-propanol 
by vol.) and the cellular protein was separated by centrifugation at 4,750 x g for 10 min 
(Allegra X-15R, Beckman Coulter Inc., Fullerton, CA).  The supernatant was collected 
into a 16 mm tube and the pellet was washed with 4 mL n-hexane: 2-propanol (HIP, 3:2 
by vol.) by vortex mixing.  After centrifugation the supernatant was combined with the 
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previous extract and the pellet was saved for protein analysis.  Extracts were stored at -20 
°C until analyzed. 
 
Quantification of Fatty Acids from BV2 Cell Cultures 
The BV2 cell lipid extract was concentrated to zero by evaporating the solvent 
under nitrogen at 65 °C and brought up in 4 mL HIP.  The extracts were concentrated to 
zero and brought up in 2 mL chloroform.  A 1 mL aliquot was transferred to a 16 mm 
tube for acid catalyzed fatty acid methyl esters (FAME)-derivatization as described 
(Akesson et al. 1970).  The samples were mixed with 50 µL of internal standard (methyl 
heptadecanoate, methyl-17:0, 276.1 pmol/µL) and concentrated to zero as above.  Dried 
samples were mixed with 4 mL 2% sulfuric acid in toluene: methanol (1:1, by Vol.), 
vortex mixed and incubated at 65 °C for 2 h with shaking at 120 rpm in a water bath.  
The tubes were cooled at 4 °C for 5 min and the samples were immediately neutralized 
with 4 mL 5% ammonium hydroxide solution in water.  Neutralized FAME were 
extracted three times with 3 mL n-hexane, collected in a 16 mm tube and concentrated to 
zero by evaporating n-hexane at 45 °C under nitrogen.  The FAME were transferred to 
microvials by dissolving in three 100 µL aliquots followed by concentration to zero using 
a SpeedVac and reconstituted in 50 µL n-hexane.  A 1–4 µL aliquot was analyzed on a 
Shimadzu GC-2010 gas chromatograph equipped with a flame ionization detector using a 
SP™-2330 capillary column (30 m x 0.32 mm x 0.2 µm film thickness; Supelco, 
Bellefonte, PA).  Detector and injection temperatures were maintained at 220 °C and 
helium was used as a carrier gas with a constant flow velocity of 30 cm/s.  Initial column 
temperature was maintained at 175 °C for 7 min followed by a gradient increase at 3 °C 
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per min to 200 °C and held constant for 9.5 min.  Fatty acid standards were used to 
identify and quantify the fatty acids in the samples based on their retention times and 
concentration factors, respectively using the Simadzu EZStart software (build 14, version 
7.2.1 SP1, Kyoto, Japan).  Fatty acid standards were used to identify and quantify the 
fatty acids in the samples based on their retention times and concentration factors, 
respectively. 
 
TLC Separation and Phospholipid Analysis 
Cellular lipid extracts, dissolved in chloroform, were isolated on 20 cm x 20 cm 
TLC Silica gel 60 plates (EMD Chemicals Inc., Gibbstown, NJ) using 
chloroform/methanol/glacial acetic acid/water (50:37.5:3:2, by Vol.) solvent system 
(Jolly et al. 1997).  Samples and standard were spotted on heat activated plates, dried for 
5 min at 85 °C then placed into the TLC chamber that was pre-equilibrated with the 
solvent system for at least 1 h.  The solvent front was allowed to reach the top of the plate 
after which the plates were air dried and bands were visualized using iodine vapors.  
Sample bands corresponding to the phospholipid standards were scraped and placed in 
acid washed tubes for phosphorus assay.  Total phospholipid mass was measured by 
quantifying the phosphorus content of the TLC separated sample bands as described 
(Rouser et al. 1966) using KH2PO4 dissolved in deionized distilled water (0.03–1.0 mM) 
as standard at 797 nm.  The sample phospholipid content for each class is expressed as 





Cholesterol levels in BV2 cell lipid extracts were measured by a method describe 
by (Bowman & Wolf 1962).  One half of the lipid extract dissolved in chloroform was 
transferred to a test tube and dried to zero under nitrogen at 45 °C.  The dried sample was 
dissolved in 500 µL ethanol (200 proof) and 500 µL of freshly prepared 0.2 % ferric 
chloride in sulfuric acid containing 8% phosphoric acid was slowly added.  Samples were 
vortex mixed for 5 min and centrifuged until the samples reached room temperature.  The 
cholesterol content was determined by measuring sample and standard cholesterol (0.94–
120 µg) absorbance at 550 nm.  Total cholesterol content was normalized to total cellular 
protein and is expressed as µg cholesterol per mg protein. 
 
Protein Analysis  
Protein pellets from nucleotide, phosphagen, and cardiolipin analysis were 
washed with acetone, dried using a nitrogen evaporator and then re-suspended for 24 h in 
1 mL 1 M sodium hydroxide.  The dissolved pellets were boiled for 5 min and protein 
content was measured as described (Bradford 1976) using bovine serum albumin as 
protein standard.  The total protein present in the sample was expressed as mg of total 
tissue or cellular protein and was used for normalizing metabolite levels.  For protein 
analysis from cell culture lipid extracts the protein pellet was dried over night at 55 °C in 
an oven.  Dried protein pellet was heated in 2 mL 0.2 M potassium hydroxide at 65 °C 
for 24 h in a water bath followed by Bradford protein estimation.  The protein 
concentration of samples used for the Western blot analysis was measured directly from 





All the data are expressed as means ± standard deviation (SD) with a sample size 
of 5–10 animals/cultures per group unless specified differently.  Statistical analysis for 
single–dose GTA administration experiments was performed using a Kruskal–Wallis 
nonparametric ANOVA followed by Dunn’s post hoc test for multiple comparisons.  For 
the 28 day cardiolipin, fatty acid content, neuronal mitochondria, nucleotide, and 
phosphagen analysis and interventional acetate supplementation studies the treatment 
group was compared to control using an unpaired, two-tailed, Mann–Whitney U-test.  For 
28 day acetate supplementation in the neuroinflammation model for nucleotide and 
phosphagen analysis, 14 and 28 day prophylactic treatments, in vitro Western blot, fatty 
acid content, phospholipid, and cholesterol analysis a one way parametric ANOVA with 
Tukey’s post hoc test was performed for multiple comparisons.  The statistical 
significance was set at p ≤ 0.05 and the analysis was performed using GraphPad InStat 
statistical software (Ver. 3.10, San Diego, CA) and graphs were prepared using 






Single-dose acetate supplementation reduces brain AMP levels without altering 
other nucleotides 
Because acetate supplementation is thought to stimulate brain bioenergetics by 
increasing acetyl-CoA metabolism, we measured brain nucleotide levels in control rats 
and rats treated with GTA for 2, and 4 h.  Using HPLC, we found that there were no 
differences in brain ATP (21.4 ± 2.6 to 24.3 ± 2.6 nmoles/mg protein, Figure 2A), ADP 
(15.3 ± 3.4 to 17.9 ± 1.1 nmoles/mg protein), NAD (5.6 ± 0.8 to 6.6 ± 0.7 nmoles/mg 
protein), or GTP (4.9 ± 0.5 to 5.7 ± 1.0 nmoles/mg protein) levels.  The control 
nucleotide values observed in this study are comparable to the reported values obtained 
using 6 kW (2 sec) microwave irradiation to stop brain metabolism (Delaney & Geiger 
1996).  On the other hand, brain AMP levels were significantly decreased at 4 h 
following treatment (5.4 ± 0.8 to 3.6 ± 1.2 nmoles/mg protein, Figure 2B).  The 
calculated energy charge ratio [ECR, (ATP + ½ ADP) / (ATP + ADP + AMP)], which 
incorporates the complete adenylate pool remained unchanged between GTA treated 
(0.73 ± 0.06) and control rats (0.70 ± 0.02).  The lack of changes in the ECR can be 
explained by the relatively smaller proportion of AMP compared to ATP and ADP.  To 
further substantiate these findings nucleotide stability and recovery studies were 
performed using radio-labeled ATP, ADP, and AMP.  Figure 3A depicts the separation 
of the different nucleotides from brain tissue samples.  The separation was reproducible 
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with average retention times of 9.4 ± 0.2, 14.0 ± 0.2, 23.4 ± 0.1, 29.5 ± 0.2, and 31.5 ± 
0.2 min for NAD, AMP, ADP, GTP, and ATP, respectively.  Nucleotide standards 
showed a linear relationship between nucleotide amount and peak area over the range of 





C] ADP, and [
14
C] AMP (90, 98, and 97% pure) were used to measure the 
extraction recovery of adenine nucleotides.  Known amounts of radioactivity was added 
to the sample before extraction, the corresponding peaks after elution were collected, and 
the nucleotide recovery was measured using liquid scintillation counting (LS 6500, 
Beckman Coulter, Fullerton, CA).  The total nucleotide recovery was 103.4 ± 3.2% and 
the individual recoveries for ATP, ADP, and AMP were 103.2 ± 2.4%, 103.1 ± 5.1%, and 
112.0 ± 3.1% (n=6), respectively.  This data suggests that the extraction of nucleotides 
was complete and extraction loss was minimal.   
 
Single-dose acetate supplementation increases brain phosphocreatine levels 
Because adenine nucleotides are tightly regulated by negative feedback 
mechanisms, under normal conditions their levels remain stable (Wallimann et al. 1992).  
Therefore, if acetate is utilized in the TCA cycle the generated energy is conserved in the 
form of PCr (Meyer et al. 1984).  Thus, creatinine (Cn), Cr, and PCr (phosphagen) 
analysis was performed to determine the effect that acetate supplementation has on 
stimulating brain energy reserves using HPLC.  We found that acetate supplementation 
significantly increased brain PCr levels (Figure 4) and the PCr/Cr ratio at 4 h (0.54 ± 







Figure 2:  Single-dose acetate supplementation reduces brain AMP levels without altering ATP levels. 
Quantification of brain ATP (Panel A) and AMP levels (Panel B) in control, and GTA-treated rats that were subjected to microwave 
fixation at 2, and 4 h post GTA treatment.  Data represent mean ± SD (nmol/mg protein), n= 8, 7, and 9 for Control, 2, and 4 h post 
GTA treatment, respectively.  Statistical analysis was performed using Kruskal-Wallis nonparametric ANOVA followed by Dunn’s 




Figure 3:  Representative HPLC chromatograms for nucleotide and phosphagen 
analysis from brain tissue. 
Panel A illustrates the elution order of nucleotides (NAD, AMP, ADP, GTP, ATP) and 
Panel B shows elution order of phosphagens (Cn, Cr, PCr) from microwave-fixed brains.  
Abbreviations are: ATP, adenosine triphosphate; ADP, adenosine diphosphate; AMP, 
adenosine monophosphate; GTP, guanosine triphosphate; NAD, nicotinamide adenine 
dinucleotide; PCr, phosphocreatine; Cr, creatine; and Cn, creatinine.  Solid lines 
represent the absorbance measured at 260 nm (Panel A) and 210 nm (Panel B) and the 
dashed line represent the gradient of buffer B (percent of total).
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brain Cr and Cn levels being 106.3 ± 13.7 to 119.5 ± 7.7, and 4.0 ± 0.4 to 4.8 ± 1.1 
nmoles/mg protein, respectively.  In this separation, the concentration of the ion-pairing 
reagent (TBAP) was reduced to 2.3 mM.  The addition of TBAP or the gradient elution 
did not affect the phosphagen separation.  However, both were essential to increase the 
retention time and ensure complete resolution of the phosphagens from sample 
contamination and other nucleotides (Figure 3 B).  The averaged retention times of Cn, 
Cr, and PCr in brain tissue samples were 2.2 ± 0.0, 2.9 ± 0.0 and 6.5 ± 0.0 min, 
respectively.  Phosphagen standards were prepared in water and a linear response was 
observed over the range of 37.50–1200 µM for Cr and 18.75–600 µM for Cn and PCr. 
 
Figure 4:  Single-dose acetate supplementation increases brain phosphocreatine 
levels. 
Quantification of brain PCr levels in control and GTA-treated rats that were subjected to 
microwave fixation at 2, and 4 h post treatment.  Abbreviations are: PCr, 
phosphocreatine.  Data represent mean ± SD (nmol/mg protein), n= 8, 7, and 9 for 
Control, 2, and 4 h post GTA treatment, respectively.  Statistical analysis was performed 
using Kruskal-Wallis nonparametric ANOVA followed by Dunn’s post hoc test and the 
statistical significance is reported comparing treatment duration to control values (*, p < 
0.05 ).  
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Single-dose and long-term acetate supplementation do not alter brain glycogen 
content 
Another energy reserve available to the brain is astrocytic glycogen.  During 
acetate supplementation, preferential utilization of acetate by astrocytes (Waniewski & 
Martin 1998) may result in reduced glucose utilization or channeling of unused glucose 
to glycogen synthesis.  Under increased metabolic demand astrocytes support neuronal 
energy metabolism through glycogenolysis and increasing the availability of glucose for 
neurons (Dinuzzo et al. 2012).  Thus, brain glycogen levels were measured after 4 h of 
single GTA dose and 28 days of daily GTA administration.  No significant changes were 
found in brain glycogen levels with 4 h (4.02 ± 0.67 µmol/g) and 28 day GTA (4.12 ± 
0.73 µmol/g) administrations as compared to respective controls (3.78 ± 0.84 and 3.77 ± 
0.95 µmol/g).  The whole brain glycogen levels obtained in this study are comparable to 
published values found in other animal models (3.3–12 µmol/g) (Choi & Gruetter 2003, 
Cruz & Dienel 2002, Herzog et al. 2008, Morgenthaler et al. 2009).  Regional variation 
in brain glycogen levels do occur with highest levels found in pons/medulla and 
cerebellum and lowest in cortex and striatum (Brown 2004, Herzog et al. 2008, Kong et 
al. 2002).  Grey matter is also known to have higher glycogen content compared to white 
matter (Brown 2004).   
 
Long-term acetate supplementation does not alter hippocampal neuron 
mitochondrial number or whole brain cardiolipin content 
It has been shown that 4 weeks of ketogenic diet treatment in rats increases the 
number of mitochondria in hippocampal neurons (Bough et al. 2006, Nylen et al. 2009).  
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Since the primary effect of both, ketogenic diet and acetate supplementation is thought to 
be through increasing acetyl-CoA metabolism we measured the effect that long-term 
acetate supplementation had on mitochondrial biogenesis.  Thus, we quantified 
mitochondrial number in hippocampal neurons (CA3 region) of rats treated with GTA or 
water for 28 days using electron microscopy.  A representative electron micrograph of a 
hippocampal neuron in the CA3 region at a magnification of 4,000 X and 20,000 X is 
shown in Figures 5A and 5B, respectively.  Quantification of these images showed that 
there was no change in the number of neuronal mitochondria per 100 µm
2
 area when 
comparing controls to GTA-treated rats (Figure 5C).  To further quantify global changes 
in brain mitochondrial mass, we measured whole brain cardiolipin levels and cardiolipin 
fatty acid content in rats treated with either water or GTA daily for 28 days.  In 
eukaryotes, cardiolipin is exclusively found in the inner mitochondrial membrane and 
thus can be utilized as a marker for new mitochondrial synthesis (Schlame 2007, Daum 
1985).  We found that 28 day GTA treatment did not alter brain cardiolipin content 
compared to control rats (Figure 5D).  Further, treatment with GTA did not alter the fatty 
acid content of mitochondrial cardiolipin as determined using gas-liquid chromatography 
(Table 2).  Collectively, these data suggest that acetate supplementation unlike the 
ketogenic diet has no effect on neuronal mitochondrial biogenesis. 
 
Long-term acetate supplementation does not alter nucleotide or phosphocreatine 
levels in normal rats 
As we had found that a single oral dose of GTA increases PCr levels with a 







Figure 5:  Long-term acetate supplementation does not alter mitochondrial biogenesis. 
Panel A shows a representative electron micrograph of a hippocampal CA3 neuron at 4,000X, and Panel B represents a 20,000 X 
magnification of the marked region in Panel A.  Arrows indicate examples of mitochondria contained within this marked region.  
Panel C shows the quantification of mitochondria found in a 100 µm
2
 cytosol area (n=5) and Panel D shows the quantification of total 
cardiolipin levels in control and GTA-treated rats (n=6, 10, respectively).  Data presented as the mean ± SD.  Statistical analysis was 






Table 2:  Brain cardiolipin fatty acid content in control and GTA-treated rats.  
 
Fatty Acid Control GTA-treated Control GTA-treated 
nmol/mg protein Mole % 
Palmitate (PAM, 16:0) 34.6 ± 4.4 35.9 ± 7.5 9.0 ± 2.8 9.1 ± 1.5 
Stearate (STA, 18:0) 62.2 ± 13.0 61.2 ± 10.4 15.4 ± 1.8 15.7 ± 3.1 
Oleate (OLA, 18:1 n-9) 106.0 ± 30.7 114.8 ± 28.7 25.7 ± 4.6 28.4 ± 3.3 
Linoleate (LNA, 18:2 n-6) 23.3 ± 6.4 23.0 ± 8.0 5.8 ± 1.2 5.6 ± 1.5 
γ- Linolenate (18:3 n-6) 5.5 ± 0.9 4.9 ± 0.8 1.4 ± 0.4 1.3 ± 0.4 
Eicosenoate (20:1 n-9) 10.1 ± 3.0 9.0 ± 2.1 2.6 ± 0.8 2.3 ± 0.5 
Dihomo-γ-linolenate (DGLA, 20:3 n-6) 5.0 ± 1.2 4.9 ± 1.1 1.2 ± 0.2 1.2 ± 0.1 
Arachidonate (ARA, 20:4 n-6) 53.7 ± 23.7 54.8 ± 20.0 12.7 ± 4.9 13.3 ± 3.2 
Lignocerate (24:0) 4.5 ± 2.1 4.3 ± 1.5 1.0 ± 0.4 1.1 ± 0.5 
Adrenate (22:4 n-6) 8.2 ± 3.1 6.1 ± 3.3 2.0 ± 0.5 1.5 ± 0.6 
Nervonate (24:1 n-9) 4.2 ± 0.7 3.8 ± 0.7 1.1 ± 0.2 1.0 ± 0.2 
Docosahexaenoate (DHA, 22:6 n-3) 20.0 ± 9.4 18.5 ± 8.0 4.6 ± 2.0 4.5 ± 1.4 
Total fatty acid content 404.5 ± 75.9 399.3 ± 79.5   
Values represent the means ± SD from control (n = 6) and GTA-treated (n = 10) rats in units of nmol/mg protein and mole percent.  
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has on brain nucleotides and PCr levels.  In rats that were treated daily with an oral 
gavage of 6 g/kg GTA or water for a period of 28 days, acetate supplementation was 
neither able to elevate brain PCr levels (Figure 6D) nor reduce AMP levels (Figure 6B).  
Other nucleotide levels (ATP, Figure 6A; NAD and GTP not shown) and the energy 
charge ratio (Figure 6C) as with the single oral dose of GTA were unaltered.  These 
findings were rather surprising and stimulated us to investigate the effects of long-term 
acetate supplementation in a rat model of neuroinflammation. 
 
Long-term acetate supplementation does not alter nucleotide or phosphocreatine 
levels in rats subjected to LPS-induced neuroinflammation 
Since loss of energy has been linked to various neurodegenerative disorders and 
neuroinflammation (Block et al. 2007, Di Filippo et al. 2010, Di Filippo et al. 2006), we 
investigated whether chronic inflammation and acetate supplementation can alter brain 
nucleotide and PCr levels.  Nucleotide and phosphagen levels were measured in 
microwave-fixed brain from rats subjected to LPS-induced neuroinflammation that were 
treated daily with 6 g/kg GTA or water for 28 days.  We found no differences in brain 
ATP (11.0 ± 2.2 to 13.9 ± 3.3 nmoles/mg protein), ADP (12.3 ± 0.3 to 16.6 ±2 .9 
nmoles/mg protein), AMP (3.0 ± 0.4 to 3.8 ± 0.8 nmoles/mg protein), ECR (0.65 ± 0.03 
to 0.65 ± 0.04), NAD (1.5 ± 1.0 to 3.4 ± 2.5 nmoles/mg protein), GTP (2.2 ± 0.8 to 3.1 ± 
0.8 nmoles/mg protein), PCr (8.6 ± 4.0 to 21.3 ± 13.3 nmoles/mg protein), Cr (119.9 ± 
8.3 to 159.9 ± 25.4 nmoles/mg protein), or Cn (5.9 ± 0.6 to 8.6 ± 1.7 nmoles/mg protein) 
levels.  Collectively, these data show that long-term acetate supplementation does not 







Figure 6:  Long-term acetate supplementation does not alter brain nucleotide or phosphocreatine levels in normal rats. 
Quantification of brain ATP (Panel A), AMP levels (Panel B), energy charge ratio [{ATP+(0.5*ADP)}/(ATP+ADP+AMP), Panel C], 
and phosphocreatine levels (PCr, Panel D) in control and GTA-treated rats, that were subjected to microwave fixation after 28 days of 
treatment.  Data represent mean ± SD, n= 6, and 10 for control, and 28 day post GTA treatment, respectively.  Statistical analysis was 
performed using two-tailed unpaired Mann-Whitney U-test with the threshold for statistical significance set at p ≤ 0.05.
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treatment for 28 days during LPS-induced neuroinflammation attenuates neuroglia 
activation (Reisenauer et al. 2011) and nucleotides play a crucial role in regulating 
inflammation (Di Virgilio et al. 2009b).  Therefore, we proposed that during long-term 
acetate supplementation brain may adapt to continuously elevated acetyl-CoA levels by 
altering purine nucleotide metabolism.   
 
Long-term acetate supplementation alters the levels of adenosine metabolizing 
enzymes and receptors in a rat model of neuroinflammation 
Purine nucleotides in addition to being energy storage units are important 
signaling molecules in the brain (Burnstock 1997).  Both ATP and its breakdown product 
adenosine are key molecules that modulate the inflammatory response in brain (Di 
Virgilio et al. 2009a).  Adenosine levels in the brain are a 1000-fold lower than adenine 
nucleotides and a delay in brain fixation by a few seconds can result in nucleotide 
breakdown elevating adenosine level by a 1000-fold.  Hence, accurate quantification of 
brain adenosine levels that resemble physiological levels is a daunting challenge.  An 
alternative approach to determine whether acetate supplementation alters purine 
metabolism, increases adenosine formation or enhances the effects of physiological 
adenosine was to quantify alterations in adenosine metabolizing enzymes and adenosine 
receptors. 
To test the hypothesis that acetate supplementation modulates brain adenosine 
metabolizing enzymes (ecto-5’-nucleotidase, CD73 and adenosine kinase, AK) and 
adenosine A2A receptor levels, we measured the levels of these proteins and the activity of 
CD73 in three parallel studies.  In studies one and two, rats were subject to 
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neuroinflammation for either 14 or 28 days and received prophylactic acetate 
supplementation throughout the duration of the experiment.  A third study was performed 
in which a group of rats were subjected to 28 days of neuroinflammation then treated 
using an interventional strategy in which acetate supplementation was started on day 14 
following the start of the LPS infusion. 
14 day prophylactic acetate supplementation:  We measured the levels of CD73, 
AK, and A2AR and the activity of CD73 in rats after a 14 day study period.  In this study, 
there were three groups of rats.  Group one received sham surgery with aCSF infusion 
and oral water which served as the control group (n = 6), group two received a LPS 
infusion dissolved in aCSF with oral water (n = 12), and group three received LPS and 
were treated with daily oral doses of GTA (6 g/kg body weight) (n = 6).  Protein bands 
for CD73, AK, A2AR, and α-tubulin corresponding to molecular weights 45, 41, 42, and 
52 kDa (Figure 7A) respectively, were quantified using Western blot analysis.  We found 
that LPS significantly reduced CD73 levels by 38%, while rats that received LPS plus 
GTA did not differ from controls (95% ± 11) (Figure 7B).  Since CD73 is the rate-
limiting enzyme for adenosine formation and changes in its activity are observed in 
inflammatory conditions (Brisevac et al. 2012), CD73 activity was measured in these 
samples.  The activity of CD73 did not significantly differ between control and rats 
subjected to neuroinflammation.  However, rats receiving LPS plus GTA had a 
significant increase in activity by 31% compared to controls and rats subjected to LPS 




Figure 7:  Fourteen day prophylactic acetate supplementation alters CD73 levels, 
CD73 activity, and A2A receptor levels. 
Panel A shows representative images of the Western blot analysis for ecto-5’-
nucleotidase (CD73), adenosine kinase (AK), adenosine A2A receptor (A2AR), and α-
tubulin.  Panel B and C show CD73 levels and CD73 activity, while Panel D and E show 
AK levels and A2AR levels, respectively.  All values represent the means ± SD, n= 6, 12, 
6 for aCSF+H2O, LPS+H2O, and LPS+GTA groups respectively.  Statistical analysis was 
performed using one way parametric ANOVA with Tukey’s post hoc test and the 
threshold for statistical significance set at p ≤ 0.05.  The symbol “a” represents a 




groups (Figure 7D).  Based on these data, we measured A2AR levels and found that LPS 
infusion causes a significant increase of 50% compared to controls, while acetate 
supplementation prevented the LPS-induced increase leaving A2AR at control levels 
(Figure 7E).  These results demonstrate that prophylactic acetate supplementation has the 
capacity to prevent LPS-induced changes in CD73 and A2AR levels, and is also able to 
increase CD73 activity.  Although it is not clear whether acetate supplementation 
achieves an increase in CD73 activity through changes in gene expression or enzyme 
modification, both may be involved.  These data do however suggest that acetate 
supplementation can modulate adenosine metabolizing enzymes and A2AR levels.   
28 day prophylactic acetate supplementation:  A 28 day study was performed to 
examine the effects of acetate supplementation on brain adenosine metabolizing enzymes 
(CD73 and AK) and A2AR levels.  The infusion and treatment groups were identical to 
those described above in the 14 day prophylactic study except that the GTA treatment 
and LPS infusion were continued for 28 days.  In this study, we found that LPS 
significantly reduced CD73 levels by 28% of controls, which was not evident in rats that 
received acetate supplementation (Figure 8B).  There was no difference in CD73 activity 
between controls and rats subjected to neuroinflammation, but LPS-treated rats receiving 
acetate supplementation showed a significant increase in activity (46%) compared to 
controls and rats subjected to neuroinflammation (Figure 8C).  LPS infusion resulted in a 
significant increase in AK levels (43%) compared to control rats.  We found no change in 
AK levels in rats subjected to neuroinflammation and treated with prophylactic acetate 




Figure 8:  Twenty eight day prophylactic acetate supplementation alters CD73 
levels, CD73 activity, and AK levels. 
Panel A shows representative images of the Western blot analysis for ecto-5’-
nucleotidase (CD73), adenosine kinase (AK), adenosine A2A receptor (A2AR), and α-
tubulin.  Panel B and C show CD73 levels and CD73 activity, while Panel D and E show 
AK levels and A2AR levels, respectively.  All values represent the means ± SD, n= 6, 12, 
6 for aCSF+H2O, LPS+H2O, and LPS+GTA groups respectively.  Statistical analysis was 
performed using one way parametric ANOVA with Tukey’s post hoc test and the 
threshold for statistical significance set at p ≤ 0.05.  The symbol “a” represents a 




groups (Figure 8E).  These results demonstrate that acetate supplementation is able to 
prevent LPS-induced changes in CD73 and AK levels, and increase CD73 activity using 
a 28 day prophylactic treatment strategy.  Collectively, these studies suggest that 
neuroinflammation modulates adenosine metabolizing enzymes which can be prevented 
with prophylactic acetate supplementation.   
Interventional acetate supplementation:  The effect of interventional acetate 
supplementation (starting at 14 days post LPS infusion until the 28
th
 day of LPS infusion) 
on adenosine metabolizing enzymes (CD73 and AK) and A2AR levels was examined.  
Treatment with GTA was begun on day 14 because this is the earliest time when 
neuroglia activation, based on significant morphological changes in astrocytes and 
microglia, has been documented (Hauss-Wegrzyniak et al. 1998a) in this model.  
However, the inflammatory signaling starts as early as 6 days following LPS infusion 
(Lee et al. 2004).  LPS-treated rats receiving an interventional acetate treatment showed a 
significant increase in CD73 levels (67%) when compared to rats that received water 
(Figure 9B) but demonstrated a significantly lower CD73 activity (88%, Figure 9C).  
There was no significant difference in AK levels between rats receiving water and rats 
receiving acetate supplementation (Figure 9D).  Interventional acetate supplementation 
resulted in a significant increase in A2AR levels (155%) compared to controls (Figure 
9E).  These results demonstrate that acetate supplementation is able to modulate CD73 
and A2AR following an interventional treatment strategy.  While an increase in CD73 




Figure 9:  Interventional acetate supplementation alters CD73 levels, CD73 activity, 
and A2A receptor levels. 
Rats were infused with LPS and were divided into two groups; beginning treatment with 
water or GTA beginning on day 14.  Panel A shows representative images of the Western 
blot analysis for ecto-5’-nucleotidase (CD73), adenosine kinase (AK), adenosine A2A 
receptor (A2AR), and α-tubulin.  Panel B and C show CD73 levels and CD73 activity, 
while Panel D and E show AK and A2AR levels, respectively.  Data represent mean ± SD, 
n=8, 6 for LPS+H2O and LPS+GTA groups, respectively.  Statistical analysis was 
performed using unpaired student t-test.  The asterisk (*) represents statistical difference 
compared to LPS + H2O group (p ≤ 0.05).
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prophylactic treatment, it may be that the mechanism by which acetate exerts its effects 
takes longer to alter the activity of the enzyme. 
 
Acetate alters the levels of adenosine metabolizing enzymes and adenosine receptors 
in LPS-stimulated BV2 microglia but not in primary astrocytes 
In brain, the innate immune response is initiated by microglia and amplified by 
astrocytes, which through glial communication act to propagate the neuroinflammatory 
response.  Since both microglia and astrocytes possess purinergic (P1 and P2) receptors 
and the enzymes that regulate extracellular ATP and adenosine levels, they both are 
important modulators of purinergic signaling (Di Virgilio et al. 2009b).  Based on our in 
vivo results demonstrating that acetate supplementation reverses LPS-induced modulation 
of adenosine metabolizing enzymes and receptors, we used BV2 microglia and primary 
astrocyte cultures to identify the specific cell types responsible for the observed in vivo 
changes.  Both BV2 microglia and primary astrocytes were divided into four groups:  
group one, 10 mM sodium chloride (NaCl, osmolarity control); group two, 10 mM 
sodium acetate (NaAc, drug effect); group three, 10 mM NaCl plus 1000 ng/mL LPS 
(NaCl+LPS, inflammation group); and group four, 10 mM NaAc plus 1000 ng/mL LPS 
(NaAc+LPS, treatment group).  Experiments were conducted for 12, 24, and 48 h in both 
cell types and levels of enzymes involved in adenosine metabolism, adenosine kinase 
(AK) and adenosine deaminase (ADA); enzymes involved in adenosine formation, ecto-
5’-nucelotidase (CD73) and ecto-apyrase (CD39); and adenosine receptors, A1 and A2A 
were analyzed using Western blot analysis. 
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BV2 microglia:  With regard to enzymes involved in adenosine formation we 
found that at 48 h, LPS did not alter CD39 protein levels (Figure 10A and 10B) but 
increased CD73 levels to 2-fold (Figure 10C and 10D) above controls.  Acetate 
prevented the LPS-induced increase in CD73 levels (Figure 10C and 10D) and 
decreased CD39 levels (Figure 10A and 10B) to 0.5-fold below control (NaCl) levels.  
On the other hand, the levels of enzymes involved in adenosine metabolism, AK and 
ADA, were increased to 2- and 1.3-fold by LPS (Figure 11) and acetate prevented the 
increase in AK levels (Figure 11A and 11B) while reduced ADA levels (Figure 11C 
and 11D) to 0.5-fold below control levels.  Further, LPS increased the levels of 
adenosine A1 (Figure 12A and 12B) and A2A (Figure 12C and 12D) receptors to 1.5- 
and 2-fold compared to controls while acetate reduced A1 receptor levels by 0.7-fold 
below controls (Figure 12A and 12B) and prevented the increase in A2A receptor levels 
by LPS (Figure 12C and 12D).  No significant changes were observed in any of the 
adenosine metabolizing enzymes or adenosine receptors at 12 and 24 h of treatment.  Our 
results on AK levels and A2A receptors in BV2 microglia are similar to what we found in 
vivo, however the CD73 levels are in complete contrast to our in vivo findings.  The 
discrepancy between the in vivo and in vitro findings may be due to the differential 
expression of enzymes and receptors by different brain cell types and their relative 
contribution to whole brain analysis.  Nonetheless, our results suggest that acetate 
supplementation can reverse LPS-induced alterations in adenosine metabolizing enzymes 







Figure 10:  Acetate reduces CD39 levels and prevents LPS-induced increase in CD73 levels in BV2 microglia. 
Cultures were stimulated with 1000 ng/mL LPS for 48 h and ecto-apyrase (CD39, converts ATP and ADP to AMP, Panel A and B) 
and ecto-5’-nucleotidase (CD73, converts AMP to ADO, Panel C and D), enzymes were analyzed.  Data represent mean ± SD, n ≥ 5.  
Statistical analysis was performed using one way ANOVA followed by Tukey’s post hoc test (p ≤ 0.05).  Abbreviations are: NaCl, 
sodium chloride; NaAc, sodium acetate; LPS, lipopolysaccharide; ATP, adenosine triphosphate; ADP, adenosine diphosphate; AMP, 








Figure 11:  Acetate prevents LPS-induced increase in AK levels and reduces ADA levels in BV2 microglia. 
Cultures were stimulated with 1000 ng/mL LPS for 48 h and adenosine kinase (AK, converts ADO to AMP, Panel A and B) and 
adenosine deaminase (ADA, converts ADO to INO, Panel C and D), enzymes were analyzed.  Data represent mean ± SD, n ≥ 5.  
Statistical analysis was performed using one way ANOVA followed by Tukey’s post hoc test (p ≤ 0.05).  Abbreviations are: NaCl, 
sodium chloride; NaAc, sodium acetate; LPS, lipopolysaccharide; AMP, adenosine monophosphate; ADO, adenosine; INO, inosine; 







Figure 12:  Acetate reduces A1 receptors and prevents LPS-induced increase in A2A receptor levels in BV2 microglia. 
Cultures were stimulated with 1000 ng/mL LPS for 48 h and adenosine A1 (A1R; Panel A and B) and A2A (A2AR; Panel C and D) 
receptors were analyzed.  Data represent mean ± SD, n ≥ 5.  Statistical analysis was performed using one way ANOVA followed by 
Tukey’s post hoc test (p ≤ 0.05).  Abbreviations are: NaCl, sodium chloride; NaAc, sodium acetate; LPS, lipopolysaccharide; “a” 
represents significant difference from NaCl; “b” represents significant difference from NaCl+LPS.  
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Primary astrocyte cultures:  As stated above astrocytes play an important role in 
modulating purinergic and inflammatory signaling.  To determine whether acetate and 
LPS alter astrocytic enzymes and receptors involved in adenosine metabolism, primary 
astrocytes were treated in the same manner as BV2 microglia.  Using western blot 
analysis, we found that at 24 h, LPS increased the levels of CD39 protein to 1.7-fold 
(Figure 13A and 13B) but had no effect on CD73 protein levels (Figure 13C and 13D).  
However, acetate in presence of LPS increased CD73 levels (Figure 13C and 13D) to 
2.2-fold above controls and did not alter LPS-induced increase in CD39 levels (Figure 
13A and 13B).  On the other hand, the levels of enzymes involved in adenosine 
metabolism, AK and ADA, were not altered by LPS (Figure 14).  But acetate in presence 
of LPS increased AK levels (Figure 14A and 14B) to 3-fold above controls while had no 
effect on ADA levels (Figure 14C and 14D).  At 24 h in primary astrocyte cultures the 
adenosine A1 receptors were below the detection level and A2A receptor levels (Figure 
15A and 15B) were not altered by LPS or acetate.  No significant changes were observed 
in any of the adenosine metabolizing enzymes or adenosine receptors at 12 and 48 h of 
treatment.  Our results in primary astrocytes suggest that the increase in CD73 and AK 
enzymes by acetate in presence of LPS may be a compensatory mechanism to replenish 
intra-cellular nucleotide levels against LPS-induced increase in ATP metabolism as a 
consequence of elevated CD39 levels.  Since the changes observed in the enzymes that 
form and metabolize adenosine from the extracellular space were opposing and 







Figure 13:  Acetate increases CD73 but does not alter CD39 levels in primary astrocytes. 
Cultures were stimulated with 1000 ng/mL LPS for 24 h and ecto-apyrase (CD39, converts ATP and ADP to AMP, Panel A and B) 
and ecto-5’-nucleotidase (CD73, converts AMP to ADO, Panel C and D) enzymes were analyzed. Data represent mean ± SD, n ≥ 5.  
Statistical analysis was performed using one way ANOVA followed by Tukey’s post hoc test (p ≤ 0.05).  Abbreviations are: NaCl, 
sodium chloride; NaAc, sodium acetate; LPS, lipopolysaccharide; ATP, adenosine triphosphate; ADP, adenosine diphosphate; AMP, 
adenosine monophosphate; ADO, adenosine; “a” represents significant difference from NaCl; “b” represents significant difference 







Figure 14:  Acetate increases AK levels but does not alter ADA levels in primary astrocytes. 
Cultures were stimulated with 1000 ng/mL LPS for 24 h and adenosine kinase (AK, converts ADO to AMP, Panel A and B) and 
adenosine deaminase (ADA, converts ADO to INO, Panel C and D), enzymes were analyzed.  Data represent mean ± SD, n ≥ 5.  
Statistical analysis was performed using one way ANOVA followed by Tukey’s post hoc test (p ≤ 0.05).  Abbreviations are: NaCl, 
sodium chloride; NaAc, sodium acetate; LPS, lipopolysaccharide; AMP, adenosine monophosphate; ADO, adenosine; INO, inosine; 







Figure 15:  Acetate does not alter adenosine A2A receptor levels in primary astrocytes. 
Cultures were stimulated with 1000 ng/mL LPS for 24 h and adenosine A2A (A2AR; Panel A and B) receptors were analyzed.  Data 
represent mean ± SD, n ≥ 5.  Statistical analysis was performed using one way ANOVA followed by Tukey’s post hoc test (p ≤ 0.05).  
Abbreviations are: NaCl, sodium chloride; NaAc, sodium acetate; LPS, lipopolysaccharide; “a” represents significant difference from 
NaCl; “b” represents significant difference from NaCl+LPS.  
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Acetate increases astrocyte energy reserves but does not alter extracellular 
adenosine levels in primary astrocyte cultures or BV2 microglia 
In order to quantify extracellular adenosine levels in astrocyte and BV2 cultures 
we developed a highly sensitive HPLC method with fluorescence detection capable of 
quantifying pico-mole amounts of adenine nucleotides.  To accomplish this, we 
optimized the fluorescence derivatization conditions and the HPLC parameters and 
achieved baseline separation and accurate quantification of adenine nucleotides.  
Nucleotides were converted to their respective 1, N
6
-etheno derivatives by incubating 
with chloroacetaldehyde at pH 4.5 and 60 °C for 60 min.  Under these conditions, the loss 
of the adenine nucleotides due to hydrolysis was minimized with a derivatization yield of 
94.1% for 1, N
6
-ethenoadenosine as determined by comparison with a pure standard.  The 
optimal concentration of tetrabutylammonium phosphate (TBAP), the ion-pairing 
reagent, required to achieve a reproducible separation of the adenine nucleotides was 
found to be 0.8 mM.  The limits of detection and quantification for all adenine 
nucleotides were approximately 0.08 and 0.16 pmol, respectively.  The intra- and inter-
day variability for this method was less than 5.1% and 3.4%, respectively.  Separation of 
etheno-adenine nucleotides from a standard nucleotide mixture and astrocyte cellular 
extracts using this method are shown in Figures 16A and 16B, respectively. 
To demonstrate that the newly developed HPLC method can accurately measure 
adenine nucleotides, we measured the effect of acetate on intracellular nucleotide levels 
in primary astrocyte cultures.  Additionally, we also quantified culture phosphagen levels 
in order to validate our in vitro model by demonstrating that the alteration in brain energy 




Figure 16:  Representative HPLC chromatograms for etheno-derivatized adenine 
nucleotide analysis from cell cultures. 
Panel A shows a standard mixture of adenine nucleotides and , β-methylene adenosine 
monophosphate and Panel B shows adenine nucleotides (1:6 dilution) found in a primary 
astrocyte culture detected by fluorescence measurement at 280 nm excitation and 410 nm 
emission wavelength. Abbreviations are: ADE, adenine; ADO, adenosine; AMP, 
adenosine monophosphate; AMPCP, α, β-methylene adenosine diphosphate; ADP, 
adenosine diphosphate; ATP, adenosine triphosphate. Solid line represents relative 




were selected for this analysis since it was known that astrocytes preferentially 
metabolize acetate owing to their specialized transport characteristics (Waniewski & 
Martin 1998).  For this primary astrocyte cultures were treated with 10 mM NaAc for 1, 
2, 3, and 4 h where 10 mM NaCl for 2 h served as a control.  The control nucleotide 
values observed using this method were comparable to the physiological values expected 
to be achieved with correctly fixed cultures to prevent degradation of nucleotides 
(Balestri et al. 2007, Tang et al. 2010).  Using this method we were able to quantify low 
AMP levels that are usually undetectable in cultures by conventional methods which 
further allowed us to accurately calculate an energy charge ratio of 0.92.  With acetate 
treatment we found that intracellular ATP levels were reduced at 3 h (Figure 17A), and 
AMP levels were reduced at 4 h of treatment (Figure 17C).  Cellular ADP levels were 
significantly reduced following 1 h of acetate treatment (Figure 17B).  Despite changes 
in ADP levels starting at 1 h the total nucleotide pool was unaltered at 1 and 2 h of 
acetate treatment however a reduction by 27% was observed at 3 and 4 h (Figure 17D).  
A significant increase in the calculated energy charge ratio was found at 1 and 2 h of 
acetate treatment while at 3 and 4 h the ECR was maintained at control levels (Figure 
17E).  This demonstrates that at 1 and 2 h of acetate treatment there was an overall 
increase in the working cellular energy available to the cell.  Further, these results were 
supported by an increase in cellular PCr levels to ~3-fold at 1 and 2 h of treatment 
compared to controls (Figure 17F).  Therefore, until 2 h of acetate treatment our results 
corroborate the in vivo findings that acetate supplementation stimulates energy 




Figure 17:  Acetate increases energy charge ratio and phosphocreatine levels in 
primary astrocytes. 
Quantification of intracellular ATP (Panel A), ADP (Panel B), AMP (Panel C), total 
adenine nucleotides [(ATP+ADP+AMP), Panel D], energy charge ratio 
[{ATP+(0.5*ADP)}/(ATP+ADP+AMP), Panel E], and phosphocreatine levels (PCr, 
Panel F) in control and acetate-treated primary astrocyte cultures.  Data represent mean ± 
SD, n= 6, for control, and all acetate treatments.  Statistical analysis was performed using 
Kruskal-Wallis nonparametric ANOVA followed by Dunn’s post hoc test and the 
statistical significance is reported comparing treatment duration to control values (*, p ≤ 
0.05 ).  
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adenine nucleotide pool while the energy charge ratio and PCr levels were maintained at 
control levels.  Therefore, beyond 2 h it is possible that acetate may stimulate release of 
ATP into the extracellular medium or enhance the metabolism of intracellular adenine 
nucleotides.  Both of which suggest a subsequent increase in adenosine formation, either 
due to extracellular metabolism of released ATP or intracellular adenosine formation 
followed by release into the extracellular space.   
Based on the cellular adenine nucleotide levels and the in vitro changes in levels 
of adenosine metabolizing enzymes and receptors describe above, we measured 
extracellular levels of adenosine in primary astrocyte and BV2 microglia cells.  Using the 
same HPLC method, we found that acetate did not alter extracellular adenosine levels in 
primary astrocyte (Figure 18A) or BV2 microglia (Figure 18B) over a period of 24 and 
48 h, respectively.  The lack of changes in extracellular adenosine levels may be due to 
rapid adenosine turnover (Noji et al. 2004).  A major limitation of these experiments was 
studying the effects of acetate on microglia and astrocyte cultures in isolation.  
Consequently, mixed glial or organotypic slice cultures where the paracrine signaling 
between different cells types is preserved may be a better model to study the effects of 







Figure 18:  Acetate does not alter extracellular adenosine levels in primary astrocyte and BV2 microglia. 
Quantification of extracellular adenosine levels in primary astrocyte (Panel A) and BV2 microglia (Panel B) cultures treated with 10 
mM NaAc/NaCl in presence or absence of LPS (1000 ng/mL) over a period of 24 and 48 h, respectively.  Data represent mean ± SD, 
n= 6, for control, and all acetate treatments.  Statistical analysis was performed using Kruskal-Wallis nonparametric ANOVA 




Acetate treatment increases fatty acid content in BV2 microglia  
It is thought that acetyl-CoA derived from acetate can be utilized for lipid 
synthesis based on data that demonstrate incorporation of radio-labeled acetate into the 
cellular lipid pools (Hellman et al. 1954, Howard et al. 1974).  However, it has not been 
shown whether supplementing large concentrations of acetate can actually increase 
cellular fatty acid, phospholipid, or cholesterol content.  Therefore, we treated BV2 
cultures with 1, 5, and 10 mM of NaAc in the presence and absence of LPS (6.25 ng/ mL) 
for 2 h.  We found that acetate alone did not alter the fatty acid content of BV2 microglia.  
However, at 2 h in presence of LPS all acetate concentrations (1–10 mM) significantly 
increased the total and individual fatty acid content (Table 3–5) in BV2 microglia.   
The changes in the fatty acid content from cells treated with 10 mM NaAc in the 
presence and absence of LPS for 2 h are shown in Table 3.  With 10 mM NaAc+LPS, we 
found a 16% increase in stearate (STA, 18:0) compared to the NaCl+LPS group.  
However, increases in oleate (OLA, 18:1 n-9, 20%), vaccenate (18:1 n-7, 22%), and 
linoleate (LNA, 18:2 n-6, 18%) were observed in the NaAc+LPS group when compared 
to the control NaCl group.  Other fatty acids including palmitate (PAM, 16:0), 
eicosenoate (20:1 n-9), dihomo-γ-linolenate (DGLA, 20:3 n-6), arachidonate (ARA, 20:4 
n-6), lignocerate (24:0), adrenate (22:4 n-6), nervonate (24:1 n-9), docosahexaenoate 
(DHA, 22:6 n-3) were not altered in any of the treatment groups.  Treatment resulted in 
an overall 14% increase in the total fatty acid content of BV2 cells comparing the 
NaAc+LPS group to NaCl control.   
Surprisingly, 5 mM NaAc was able to induce greater percent increases in the fatty 






Table 3:  Fatty acid content of BV2 microglia cultures treated with 10 mM acetate in the presence and absence of LPS for 2h.  
 
Fatty Acid  nmol/mg protein 
NaCl NaAc NaCl+LPS NaAc+LPS 
Palmitate (PAM, 16:0) 40.5 ± 5.7 39.3 ± 6.2 40.8 ± 6.0 45.9 ± 10.6 
Stearate (STA, 18:0) 58.7 ± 4.9 60.5 ± 4.8 56.9 ± 5.4 
c
 66.1 ± 8.7 
Oleate (OLA, 18:1n-9) 104.7 ± 6.2 101.7 ± 3.9 105.5 ± 8.0 a,b,c 125.6 ± 13.0 
Vaccenate (18:1n-7) 27.1 ± 1.8 27.3 ± 1.3 28.9 ± 1.9 a,b,c 33.0 ± 3.1 
Linoleate (LNA, 18:2n-6) 24.0 ± 1.1 22.9 ± 0.9 24.8 ± 1.9 a,b,c 28.4 ± 3.4 
Eicosenoate (20:1n-9) 6.7 ± 1.1 5.6 ± 0.7 5.7 ± 1.1 7.1 ± 1.4 
Dihomo-γ-linolenate (DGLA, 20:3n-6) 4.0 ± 0.9 4.2 ± 0.8 3.6 ± 0.9 4.0 ± 1.3 
Arachidonate (ARA, 20:4n-6) 17.0 ± 1.9 16.3 ± 1.7 17.7 ± 2.1 19.7 ± 3.4 
Lignocerate (24:0) 5.8 ± 1.2 5.6 ± 0.9 5.0 ± 1.1 5.3 ± 1.3 
Adrenate (22:4n-6) 2.3 ± 0.4 2.1 ± 0.3 2.3 ± 0.4 2.3 ± 0.6 
Nervonate (24:1n-9) 5.2 ± 1.1 4.6 ± 0.8 4.2 ± 1.0 4.4 ± 1.3 
Docosahexaenoate (DHA, 22:6n-3) 9.7 ± 1.7 9.2 ± 1.5 9.3 ± 1.6 9.7 ± 2.4 
Total fatty acid content 351.7 ± 20.1 342.4 ± 16.3 347.7 ± 27.8 
a,b,c
 399.1 ± 42.7 
Values represent the means ± SD (n = 8) in units of nmol/mg protein; 
a,
 represents significant difference from NaCl group; 
 
b,
 represents significant difference from NaAc group; 
c, 
represents significant difference from NaCl+LPS group (p ≤ 0.05).
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5 mM NaAc+LPS resulted in increases in PAM (99%), STA (29%), OLA (51%), 18:1 n-
7 (49%), and 18:2 n-6 (54%) compared to the control NaCl group.  Other fatty acids 20:1 
n-9, DGLA, ARA, 24:0, 22:4 n-6, 24:1 n-9, and DHA were not altered in any of the 
treatment groups.  An overall increase of 34% in the total fatty acid content of BV2 cells 
was observed in the NaAc+LPS group when compared to the control groups.   
With 1 mM NaAc+LPS, we found increases in PAM (27%), STA (18%), OLA 
(27%), 18:1 n-7 (26%), and 18:2 n-6 (36%) were observed with NaAc+LPS group 
compared to the NaCl and NaAc groups (Table 5).  Fatty acid 20:1 n-9 showed a 6% 
increase from the NaAc group while a 21% and 38% increase in ARA, and DHA was 
observed with NaAc+LPS form the NaCl control.  Other fatty acid, DGLA, 24:0, 22:4 n-
6, and 24:1 n-9 were not different in any of the treatment groups.  Treatment with 1 mM 
NaAc+LPS resulted in an overall increase of 23% in the total fatty acid content in BV2 
cells when compared to the NaCl group.  Collectively, these data demonstrate that as low 
as 1 mM acetate in presence of LPS is capable of increasing individual and the total fatty 
acid content in BV2 cells supporting the hypothesis that acetate can stimulate fatty acid 
synthesis.   
 
Acetate does not alter total phospholipid content in BV2 microglia 
Since we observed a 14-34 % increase in the total fatty acid content with 
NaAc+LPS in BV2 microglia, we investigated whether this results in an increase in total 
phospholipid content.  Phosphorus mass of individual phospholipid classes separated 
using TLC was quantified as an index of the phospholipid content with 10 and 5 mM 






Table 4:  Fatty acid content of BV2 microglia cultures treated with 5 mM acetate in the presence and absence of LPS for 2h. 
 
Fatty Acid  nmol/mg protein 
NaCl NaAc NaCl+LPS NaAc+LPS 
 Palmitate (PAM, 16:0) 20.7 ± 5.4 26.0 ± 14.9 16.7 ± 4.5 a,b,c 41.3 ± 6.4 
 Stearate (STA, 18:0) 75.9 ± 17.1 86.4 ± 19.0 75.4 ± 14.5 
a,c
 98.1 ± 10.5 
 Oleate (OLA, 18:1n-9) 119.0 ± 13.7 135.0 ± 37.8 111.1 ± 14.7 a,b,c 179.9 ± 17.5 
 Vaccenate (18:1n-7) 33.3 ± 4.0 37.1 ± 10.5 31.0 ± 3.5 a,b,c 49.5 ± 4.2 
 Linoleate (LNA, 18:2n-6) 26.8 ± 2.8 31.6 ± 9.0 25.8 ± 2.5 a,b,c 41.1 ± 4.1 
 Eicosenoate (20:1n-9) 20.1 ± 14.8 10.8 ± 5.3 13.4 ± 14.9 12.2 ± 4.5 
 Dihomo-γ-linolenate (DGLA, 20:3n-6) 7.3 ± 4.2 6.4 ± 1.9 6.8 ± 3.1 6.0 ± 0.7 
 Arachidonate (ARA, 20:4n-6) 26.3 ± 8.4 28.0 ± 6.9 27.4 ± 6.9 33.9 ± 3.5 
 Lignocerate (24:0) 10.1 ± 6.8 8.9 ± 2.3 10.4 ± 4.9 8.1 ± 1.5 
 Adrenate (22:4n-6) 5.2 ± 2.4 5.4 ± 1.2 6.0 ± 2.4 5.9 ± 1.0 
 Nervonate (24:1n-9) 7.4 ± 5.2 6.1 ± 1.7 7.6 ± 3.5 6.3 ± 0.9 
 Docosahexaenoate (DHA, 22:6n-3) 17.2 ± 8.6 17.0 ± 4.1 18.5 ± 6.8 18.9 ± 2.2 
Total fatty acid content 406.8 ± 92.8 436.8 ± 114.3 385.5 ± 85.0 
a,c
 545.6 ± 53.6 
Values represent the means ± SD (n = 8) in units of nmol/mg protein; 
a,
 represents significant difference from NaCl group; 
 
b,
 represents significant difference from NaAc group; 
c, 






Table 5:  Fatty acid content of BV2 microglia cultures treated with 1 mM acetate in the presence and absence of LPS for 2h. 
 
Fatty Acid  nmol/mg protein 
NaCl NaAc NaCl+LPS NaAc+LPS 
 Palmitate (PAM, 16:0) 57.2 ± 5.3 58.8 ± 10.2 61.7 ± 6.7 
a,b
 72.5 ± 12.5 
 Stearate (STA, 18:0) 46.8 ± 4.4 48.2 ± 5.6 50.2 ± 1.5 
a,b
 55.4 ± 6.6 
 Oleate (OLA, 18:1 n-9) 99.3 ± 8.6 105.1 ± 10.8 111.9 ± 4.3 
a,b
 125.6 ± 14.1 
 Vaccenate (18:1 n-7) 26.9 ± 2.1 28.5 ± 2.9 30.4 ± 0.5 
a,b
 33.9 ± 4.5 
 Linoleate (LNA, 18:2 n-6) 23.1 ± 1.6 25.3 ± 2.6 
a
 28.1 ± 1.0 
a,b
 31.5 ± 3.9 
 Eicosenoate (20:1 n-9) 1.5 ± 0.3 1.3 ± 0.2 1.3 ± 0.1 
b
 1.6 ± 0.2 
 Dihomo-γ-linolenate (DGLA, 20:3 n-6) 1.9 ± 0.4 2.1 ± 0.4 2.0 ± 0.1 2.2 ± 0.3 
 Arachidonate (ARA, 20:4 n-6) 13.1 ± 1.5 13.9 ± 1.8 
a,b
 15.1 ± 0.5 
a,b
 15.9 ± 1.8 
 Lignocerate (24:0) 2.4 ± 0.4 2.5 ± 0.4 2.4 ± 0.1 2.6 ± 0.4 
 Adrenate (22:4 n-6) 1.7 ± 0.6 1.6 ± 0.2 1.7 ± 0.2 2.0 ± 0.4 
 Nervonate (24:1 n-9) 2.2 ± 0.3 2.4 ± 0.3 2.3 ± 0.2 2.5 ± 0.4 
 Docosahexaenoate (DHA, 22:6 n-3) 6.3 ± 0.8 7.1 ± 1.2 7.1 ± 0.6 
a
 8.7 ± 2.7 
Total fatty acid content 333.5 ± 25.3 343.4 ± 38.8 359.3 ± 13.7 
a,b,c
 408.7 ± 52.8 
 
Values represent the means ± SD (n = 8) in units of nmol/mg protein; 
a,
 represents significant difference from NaCl group; 
 
b,
 represents significant difference from NaAc group; 
c, 
represents significant difference from NaCl+LPS group (p ≤ 0.05). 
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the individual phospholipid content in any group of cells treated with either 10 or 5 mM 
NaAc+LPS compared to the NaCl group (Table 6 and 7).  These results suggest that 2 h 
of acetate treatment is not sufficient to increase overall BV2 cell phospholipid content 
suggesting the increases in fatty acid content may involve triacylglycerol, or other fatty 
acid stores.  The impact that treatment had on the fatty acid composition of the individual 
phospholipid classes was not determined.  
 
Acetate increases cholesterol levels in BV2 microglia 
An alternative pathway for acetate-derived increases in acetyl-CoA may involve 
an increase in cholesterol synthesis.  To determine if treatment altered cholesterol levels 
we quantified the total cholesterol in cells treated with either 5 or 10 mM NaAc in the 
presence and absence of LPS for 2 h.  A modest but significant increase (11 %) in the 
total cholesterol levels was observed in cells treated with 5 mM NaAc (Table 8).  
However, no significant change in the total cholesterol levels was observed with 5 mM 
NaCL+LPS or 5 mM NaAc+LPS (Table 6) compared to the NaCl group.  Cells treated 
with 10 mM NaAc in presence or absence of LPS did not alter total cholesterol levels.  
These results suggest that acetate, at lower concentrations, can increase total cholesterol 
levels similar to that found with total fatty acid content. 
 
Acetate increases histone acetylation in a time- and concentration-dependent 
manner 
To better understand the time frame of acetate-induced increase in histone acetylation, we 











NaCl NaAc NaCl+LPS NaAc+LPS 
Ethanolamine glycerophospholipids(EtnGpl) 73.5 ± 22.4 85.7 ± 2.7 72.1 ± 14.4 80.0 ± 6.1 
Choline glycerophospholipids (ChoGpl) 139.9 ± 17.0 144.6 ± 11.6 158.1 ± 11.8 166.1 ± 16.4 
Sphingomyelin (CerPCho) 49.0 ± 14.5 61.7 ± 12.3 62.5 ± 11.5 87.4 ± 27.1 
Phosphatidylinositol (PtdIns) 44.3 ± 18.2 36.3 ± 5.4 38.3 ± 13.1 37.6 ± 16.1 
Phosphatidylserine (PtdSer) 32.3 ± 10.3 46.1 ± 19.2 40.6 ± 16.7 42.4 ± 12.8 










NaCl NaAc NaCl+LPS NaAc+LPS 
Ethanolamine glycerophospholipid (EtnGpl) 58.2 ± 14.8 77.7 ± 15.1 62.5 ± 14.4 65.8 ± 18.4 
Choline glycerophospholipid (ChoGpl) 119.9 ± 16.1 108.3 ± 23.2 96.5 ± 34.7 129.9 ± 22.0 
Sphingomyelin (CerPCho) 36.7 ± 3.5 39.2 ± 11.1 35.7 ± 9.6 44.0 ± 13.2 
Phosphatidylinositol (PtdIns) 13.7 ± 8.1 22.7 ± 3.5 22.2 ± 9.4 20.1 ± 6.2 
Phosphatidylserine (PtdSer) 23.8 ± 5.7 27.4 ± 7.5 26.9 ± 13.5 19.3 ± 2.9 
Values represent the means ± SD (n = 4) in units of nmol/mg protein. 
 
Table 8:  Cholesterol content of BV2 microglia treated with 5 and 10 mM acetate in presence or absence of LPS for 2 h. 
 
Concentration 
Cholesterol content (µg/mg protein) 
NaCl NaAc NaCl+LPS NaAc+LPS 
10 mM 61.1 ± 6.2 57.1 ± 4.5 60.3 ± 6.1 52.5 ± 5.1 
5 mM 66.9 ± 2.6 
a
 74.8 ± 3.8 68.4 ± 4.5 73.5 ± 2.4 
Values represent the means ± SD (n = 4) in units of nmol/mg protein.
 a,
 represents significant difference from NaCl group; (p ≤ 0.05).
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and 4 h in BV2 microglia.  Earlier using these cells we showed that, 12 mM NaAc 
increases H3K9 acetylation at 2 and 4 h (Soliman et al. 2012a).  However, in this study 
we found that 10 mM NaAc was only able to increase H3K9 acetylation at 4 h to 3.4-fold 
over control levels (Figure 19A and 19B).  On the other hand, acetylation of histone H4 
at multiple lysine and/or serine residues was increased to approximately 2-, 2.5- and 5.2-
fold (Figure 19C and 19D) following 0.5, 2, and 4 h of acetate treatment, respectively.  
Histone H4 acetylation at 4 h was significantly higher than 0.5 and 2 h acetate treatment 
suggesting that acetate-induced acetylation is progressive and not limited to H3K9.  In 
order to determine the lowest concentration of acetate required to increase the 
acetylation-state of nuclear histones, we measured the concentration effect of acetate 
treatment (0.5, 1, 5, and 10 mM) on the acetylation-state of histones H3 and H4.  We 
found a significant increase in H3K9 acetylation (1.9- and 2.1-fold) in cells treated with 5 
and 10 mM NaAc (Figure 20A and 20B).  However, the acetylation-state of H3 was not 
altered in cells treated with 0.5 or 1 mM NaAc compared to NaCl controls.  Similarly, H4 
acetylation was increased with 5 and 10 mM NaAc to 2.3- and 3.8-fold (Figure 20C and 
20D) over controls while 0.5 and 1 mM NaAc had no effect.  Unlike H3K9, the 
acetylation-state of H4 with 10 mM NaAc was significantly higher than 5 mM NaAc 
suggesting that higher acetate concentrations have the potential to induce acetylation of 
multiple acetylation sites on H4.  Thus, these data suggest that a minimum concentration 








Figure 19:  Acetate increases histone H3 and H4 acetylation-state in a time-dependent manner in BV2 microglia. 
Western blot analysis was performed following 0.5, 2, 4 h of acetate (10 mM) treatment to determine temporal changes in acetylated 
H3K9 (Panel A), and acetylated H4S1/K5/K8/K12 (Panel C), normalized to total H3 (Panel A) and total H4 (Panel C), respectively.  
Panel B and D show quantification of the changes in the acetylation-state of histone H3 and H4, respectively.  Data represent mean ± 
SD (n=3, p ≤ 0.05) where a, b, and c represent statistically significant difference from 0.5, 2 and 4 h sodium chloride (NaCl) while α, 







Figure 20:  Acetate increases histone H3 and H4 acetylation-state in a concentration-dependent manner in BV2 microglia. 
Western blot analysis was performed with 0.5, 1, 5, and 10 mM acetate (4 h) to determine concentration-dependent changes in the 
acetylated H3K9 (Panel A), and acetylated H4S1/K5/K8/K12 (Panel C), normalized to total H3 (Panel A) and total H4 (Panel C), 
respectively.  Panel B and D show quantification of the changes in the acetylation-state of histone H3 and H4, respectively.  Data 
represent mean ± SD (n=3, p ≤ 0.05) where a, b, c, and d represent statistically significant difference from 0.5, 1, 5 and 10 mM sodium 





Acetate supplementation increases plasma acetate by 100-fold (19.3 ± 4.72 mM) 
in rats (Reisenauer et al. 2011) and brain acetate by 17-fold (8.5 µmol/g brain ~10.6 mM) 
in mice (Mathew et al. 2005) treated with a single oral dose of 6 or 5.8 g/kg body weight 
glyceryl triacetate (GTA), respectively.  Acetate crosses the blood brain barrier 
(Deelchand et al. 2009) and is preferentially taken up by astrocytes through facilitated 
transport via monocarboxylate transporters (MCT) (Waniewski & Martin 1998).  Acetate 
is further activated to acetyl-CoA by either cytosolic or mitochondrial acetyl-CoA 
synthetase enzymes (Hallows et al. 2006).  In support of this mechanism, acetate 
supplementation increases brain acetyl-CoA levels by 2.2-fold (5.7 ± 1.9 µg/g tissue ~8.7 
± 2.9 µM) within 30 min and remains elevated out to 4 h following treatment (Reisenauer 
et al. 2011).  Acetyl-CoA is a substrate for various pathways including protein 
acetylation, the TCA cycle, and lipid synthesis.  Regarding protein acetylation, single and 
multiple oral doses of GTA increase acetylation of histone and non-histone proteins that 
in turn alter inflammatory gene expression (Soliman & Rosenberger 2011, Soliman et al. 
2012b).  However, the influence that acetate supplementation has on brain purine and 
lipid content has not been tested.  Therefore, we sought to measure the effect that single 
and multiple oral doses of GTA had on brain nucleotides, phosphagens, and 
mitochondrial biogenesis in normal rats.  We found that 4 h after a single oral GTA 
administration, brain PCr levels were increased (Bhatt et al. 2013) significantly compared
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to controls (Figure 4), consistent with the increase in brain acetyl-CoA levels 
(Reisenauer et al. 2011).  However, changes in brain ATP (Figure 2A), ADP, GTP, or 
NAD levels (listed in results) remain unaltered.  Furthermore, daily GTA administration 
for a period of 28 days in normal rats (Figure 6) or rats subjected to LPS-induced 
neuroinflammation (listed in results) did not alter PCr or brain nucleotide levels.  
The metabolic half-life of ATP is only a few milliseconds and is controlled by a 
balance of cellular energy supply and demand (Erecinska & Silver 1989).  In these 
experiments, rats were not challenged by noxious stimuli nor was there an increase in the 
energy demand due to disease pathology.  Thus, we speculate that the energy generated 
as a result of mitochondrial acetyl-CoA metabolism would be stored in the form of PCr.  
ATP and other adenylate metabolites are key regulators of metabolic pathways that 
maintain cellular homeostasis and thus their levels are tightly regulated (Wallimann et al. 
1992).  Phosphocreatine, on the other hand, is metabolically inert with regard to 
biochemical regulation and serves as a reservoir of energy (Wallimann et al. 1992).  
During increased metabolic demand or diseased states, the brain can utilize PCr to 
maintain ATP levels (Meyer et al. 1984).  Following injury, a decrease in PCr levels 
precedes ATP loss (Lowry et al. 1964, Norberg et al. 1975) and thus it is important to 
monitor and maintain both ATP and PCr levels.  In this regard, acetate supplementation 
partly restores brain ATP levels in a rat model of traumatic brain injury (Arun et al. 
2010a), however PCr levels were not measured in this study and the ATP restoration may 
have been secondary to the neuroprotective effects of GTA.  Our results substantiate 
these findings by demonstrating that acetate supplementation can directly influence basal 
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PCr levels.  Since labeled-acetate is known to enter the glial glutamine pool it may be 
argued that the observed changes in PCr levels, in this study, predominantly reflect 
changes occurring in astrocytes.  However, mitochondrial creatine kinase, the enzyme 
responsible for PCr formation, is selectively expressed in neurons but not in astrocytes 
whereas the cytosolic form of creatine kinase is expressed by both the cell types 
(Tachikawa et al. 2004).  Thus, analysis of changes in PCr levels in individual cell types 
in vitro is required to determine which cell type contributes towards an increase in PCr 
levels.  Further, during long-term acetate supplementation the brain may adapt to 
constantly elevated acetyl-CoA levels by diverting its utilization to other pathways like 
glycogen synthesis, lipid synthesis, purine metabolism or protein acetylation.  As 
mentioned earlier, we have shown that GTA induces histone acetylation in a rat model of 
neuroinflammation and is associated with decrease in interleukin-1β expression (Soliman 
et al. 2012b).  Therefore, we measured the effect of GTA and/or acetate on glycogen 
levels, purine metabolism, and lipid content in in vivo and in vitro models as described 
below. 
At 4 h of single-dose acetate supplementation there was a modest but significant 
reduction in brain AMP levels (Figure 2B) which coincide with the increase in PCr 
levels.  The creatine-phosphate shuttle is responsible for the transfer of high energy 
phosphate between PCr/Cr and ATP/ADP, however AMP is not involved in this transfer 
(Meyer et al. 1984).  Since we did not observe significant changes in the ATP, ADP or Cr 
levels, there appears to be a discrepancy between increases in PCr levels and its 
biochemical relationship to other components of the creatine kinase system.  This may 
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partially be explained by increase in free [Mg
2+
] as a result of ATP hydrolysis induced by 
microwave irradiation (Srivastava et al. 2012) and subsequent changes in the equilibrium 
constant of the creatine kinase reaction (Lawson & Veech 1979).  Nonetheless, given the 
increase in PCr and the tight control over cellular ATP and ADP levels under normal 
conditions the observed reduction in AMP suggests an overall increase in the cellular 
energy supply.  Alternatively, increased acetyl-CoA may result in a situation where AMP 
can be metabolized to adenosine.  In the brain, adenosine levels are in the picomolar 
range while AMP levels are in the nanomolar range (Delaney & Geiger 1996), which 
suggests that a small change in AMP can lead to a dramatic increase in brain adenosine.  
In support of this, it has been demonstrated that acetate uptake by neurons induces 
intracellular acidosis resulting in stimulation of the sodium hydrogen exchanger and the 
sodium potassium ATPase which consume ATP and result in adenosine release (Zamzow 
et al. 2006).  Adenosine is known for its anti-inflammatory and neuroprotective 
properties (Cunha 2005, Ribeiro 2005), and acetate supplementation attenuates neuroglia 
activation and prevents loss of choline-acetyl transferase immuno-reactivity in rats 
subjected to neuroinflammation (Reisenauer et al. 2011).  Consequently, this suggests 
that increasing mitochondrial energy reserves and possibly adenosine levels may 
contribute to the neuroprotective and anti-inflammatory effects of acetate 
supplementation.  However, since acetyl-CoA is a ubiquitous substrate for various 
biochemical pathways there can be multiple mechanisms underlying the beneficial effects 
of acetate supplementation.  Although increase in energy is beneficial, a direct link to the 
anti-inflammatory effect of acetate supplementation remains elusive.  Since in the brain, 
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ATP and adenosine modulate inflammation through purinergic receptor signaling (Di 
Virgilio et al. 2009b) altering purine levels and their receptor expression has the potential 
of disrupting the neuroinflammatory response.   
An alternative energy reserve available to the brain is glycogen, which is 
primarily localized in astrocytes as cytoplasmic granules.  Although brain glycogen is 
primarily localized in astrocytes the enzyme glycogen synthase involved in glycogen 
synthesis is expressed in neurons as well as astrocytes.  Alternatively, glycogen 
phosphorylase, the enzyme responsible for glycogen breakdown is primarily astrocytic 
(Brown 2004).  Since acetate is preferentially utilized by astrocytes it is possible that in 
our experiments acetate utilization may divert glucose towards glycogen synthesis in 
astrocytes or rather spare glucose for neuronal utilization.  During insulin-induced 
hypoglycemic conditions, brain glycogen levels fall in areas with high metabolic rate, 
suggesting that brain glycogen is used to support brain energetics (Brown 2004).  Thus, 
we measured brain glycogen levels in animals treated with GTA for 4 h, and 28 days.  
Interestingly, single-dose and long-term acetate supplementation did not alter brain 
glycogen levels.  Estimated glycogen turnover rates are between 5-10 h (Choi & Gruetter 
2003, Morgenthaler et al. 2009) which explains the absence of changes in glycogen 
levels with 4 h of GTA treatment.  Further, a 28 day treatment regimen is sufficient to 
observe any significant changes in glycogen synthesis.  However, absence of changes in 
glycogen with long-term treatment suggests that GTA does not affect brain glycogen 
synthesis or during this long period the reserve energy is utilized for other biochemical 
pathways.  As stated above, same can be true with acetate utilization, owing to its 
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ubiquitous nature acetyl-CoA may be channeled into other metabolic pathways like lipid 
synthesis or protein acetylation.  In this regard, acetate supplementation increases brain 
histone acetylation in vivo and in vitro in astrocyte and microglial cultures (Soliman et al. 
2013a, Soliman et al. 2012a, Soliman & Rosenberger 2011, Soliman et al. 2012b).  
Nonetheless, acetate utilization by astrocytes may reduce glial glucose utilization and 
increase neuronal glucose availability.   
Alternatively, it is possible that under significantly high acetate levels achieved 
with acetate supplementation, neurons may also utilize acetate for energy production.  
The molecular basis for astrocyte-specific uptake of acetate has only been tested by two 
studies with conflicting results.  Rat cortical astrocytes generate labeled-CO2 18 times 
faster than cortical synaptosomes suggesting that acetate is preferentially utilized by 
astrocytes compared to neurons (Waniewski & Martin 1998).  However, it is possible that 
alternative TCA cycle intermediates are synthesized in astrocytes verses neurons or that 
acetate-derived acetyl-CoA is channeled into different biochemical pathways by the two 
cell types.  Waniewski and Martin attribute the difference in labeled-CO2 production to 
the selective uptake of acetate by astrocytes via monocarboxylic acid-like transporters 
(Waniewski & Martin 1998).  However, neurons are known to express monocarboxylic 
acid transporters (Pierre & Pellerin 2005) and the activity of acetyl-CoA synthetase, the 
enzyme responsible for acetate utilization, is higher in synaptosomes (Waniewski & 
Martin 1998) suggesting that neurons can also transport and utilize acetate.  This is 
substantiated by studies demonstrating that neuronal MCT2 transports acetate with 
affinities comparable to that of astrocytic MCT1 (Km ~1.6–2.5 mM) (Rae et al. 2012), 
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however acetate transport may be limited in presence of lactate (Moschen et al. 2012).  
On the other hand, Brand et al. demonstrated that acetate can be metabolized by both the 
cell types and that in neurons acetate-derived labeled-carbon is recovered as glutamate 
and aspartate while in astrocytes as glutamine (Brand et al. 1997).  The major difference 
between the experimental paradigms of these two studies is the concentration of labeled-
acetate used, 0.2 and 5 mM, respectively.  Moreover, most in vivo glial metabolism 
studies utilize labeled-acetate at either physiological (~0.2 mM) or much lower levels 
which are well below normal glucose levels where acetate utilization is primarily 
astrocytic.  Brain acetate levels achieved with GTA administration are approximately 10 
mM (8.5 µmol/g brain) (Mathew et al. 2005), twice the normal glucose levels (5 mM).  
Thus, at such high acetate concentrations the excess acetate may be utilized by neurons, 
especially considering that synaptosomes have significantly higher acetyl-CoA synthetase 
activity compared to astrocytes (Waniewski & Martin 1998).  At this point it cannot be 
attributed whether the observed in vivo effects of acetate supplementation are 
predominantly astrocytic or neuronal.  However, future in vitro studies measuring the 
effect of different acetate concentrations on individual cell types could allow us to make 
the necessary distinction. 
Because acetate supplementation and ketogenic diet share a common metabolic 
intermediate, acetyl-CoA, it is important to understand the influence that acetate 
supplementation has on mitochondrial biogenesis.  Ketogenic diet being a high-fat low-
carbohydrate diet enhances hepatic β-oxidation of free fatty acids and increases 
circulating levels of β-hydroxy butyrate (BHB), the predominant ketone body, from 0.2 
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mM to 3.9 mM in mouse plasma (Yudkoff et al. 2005).  In brain, the uptake of ketones 
across the BBB is mediated by monocarboxylic acid transporters where they are taken up 
by both neurons and astrocytes (Cremer 1971, Melo et al. 2006).  Once inside the cell, 
BHB bypasses the glycolytic steps, enters the mitochondria, and is converted into 
acetoacetate, acetoacetyl-CoA, and finally acetyl-CoA based on NAD
+
 availability 
(White & Venkatesh 2011).  Ketone bodies formed as a result of 4 weeks on a ketogenic 
regimen increase the number of mitochondria in hippocampal neurons (Bough et al. 
2006).  However, we found that a 28 day treatment with GTA did not alter hippocampal 
CA3 neuronal mitochondrial number (Figure 5).  Post-synaptic inter-neurons in the CA3 
region receive axonal input from entorhinal cortex and dentate gyrus and relay 
information to the CA1 cell bodies.  Since acetate is preferentially utilized by glia 
(Waniewski & Martin 1998), absence of changes in neuronal mitochondrial number does 
not exclude changes in astrocytic mitochondria.  Thus, to detect global changes in 
mitochondrial mass, we quantified cardiolipin levels and cardiolipin fatty acid content in 
whole brain.  However, we did not find significant changes in whole brain mitochondrial 
mass or cardiolipin fatty acid composition (Table 1).  This suggests that acetate 
supplementation does not significantly alter the synthesis of new mitochondria in whole 
brain although changes in their size and distribution in specific brain compartments 
cannot be ruled out.  We primarily focused on comparing the known effects of ketogenic 
diet on mitochondrial biogenesis in hippocampal neurons with that of acetate 
supplementation.  Nonetheless, considering the preferentially utilization of acetate by 
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astrocytes, investigation of how acetate supplementation affects astrocytic mitochondrial 
biogenesis is required.   
One of the proposed mechanisms by which the ketogenic diet increases 
mitochondrial biogenesis is activation and increased expression of the transcription 
factor, peroxisome proliferator-activated receptor gamma co-activator 1 alpha (PGC-1α) 
(Wallace et al. 2010).  PGC-1α is considered as the master regulator of mitochondrial 
biogenesis and is regulated by reversible acetylation.  Sirtuin 1 (Sirt1) is a NAD
+
-
dependent cytosolic protein deacetylase that activates PGC-1α by removing the acetyl 
group (Rodgers et al. 2005).  Since ketone bodies are utilized exclusively inside the 
mitochondria they spare cytosolic NAD
+
 which is normally consumed during glycolytic 
metabolism (Wallace et al. 2010).  This activates Sirt1 resulting in deacetylation of PGC-
1α and induction of mitochondrial biogenesis.  Further, limited carbohydrate availability 
with ketogenic diet reduces insulin levels and enhances glucagon secretion both of which 
through independent signaling pathways up-regulate PGC-1α expression and thus induce 
mitochondrial biogenesis (Wallace et al. 2010).  Acetate supplementation, on the other 
hand, does not reduce carbohydrate availability, elevates cytoplasmic and mitochondrial 
acetyl-CoA levels, and as suggested earlier may increase neuronal glucose availability.  
Thus, cytosolic acetyl-CoA through protein acetylation may maintain the normal 
acetylation-state of PGC-1α and prevent induction of mitochondrial biogenesis.  It can be 
argued that like ketone bodies, acetate may also spare cytosolic NAD
+
 and activate Sirt1 
to induce mitochondrial biogenesis.  However, another effect of Sirt1 activation is that it 
activates acetyl-CoA synthatase by NAD
+
-dependent deacetylation (Wilhelm & 
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Hirrlinger 2012).  Thus, this utilized NAD
+
 and elevates acetyl-CoA levels which can be 
used to maintain normal acetylation-state of PGC-1α and mitochondrial biogenesis.  The 
exact mechanisms that regulate acetate utilization in different cellular compartments are 
still unclear however this may partially explain the differential effects of ketogenic diet 
and acetate supplementation on mitochondrial biogenesis.  Therefore, while the two 
treatments share similarity at increasing acetyl-CoA levels our results suggests that 
acetate supplementation unlike the ketogenic diet does not result in mitochondrial 
biogenesis.  
The accurate determination of high-energy phosphates requires rapid brain 
fixation to instantaneously stop their metabolism.  Head-focused microwave irradiation is 
a quick technique to rapidly inactivate enzymes while preserving the structural integrity 
of the brain.  For in vivo nucleotide and phosphagen analysis we used 6 kW output power 
with a 2 sec exposure, as described (Delaney & Geiger 1996).  Consequently, the 
nucleotide content obtained in this study closely resembles the reported values obtained 
using comparable microwave conditions (Delaney & Geiger 1996, Gupta & Dettbarn 
2003).  Nonetheless, brain ATP levels obtained by microwave fixation are lower, and 
ADP and AMP levels are subsequently higher than those obtained by freeze blowing or 
in-situ funnel freezing techniques (Ponten et al. 1973, Veech et al. 1973).  In addition to 
differential inactivation of nucleotide metabolizing enzymes (Nelson 1973), microwave 
irradiation can directly break the high energy phosphate bond in ATP and result in an 
approximate 30% ATP loss compared to the freeze blowing method (Srivastava et al. 
2012).  The phosphate bond in PCr is however stable to thermal degradation and creatine 
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kinase, the enzyme that converts PCr to creatine, is efficiently inactivated by microwave 
irradiation (Nelson 1973) resulting in PCr values similar to those obtained with freeze 
blowing (Srivastava et al. 2012).   
In order to integrate GTA-induced changes in energy levels with the potential to 
alter purinergic metabolism, we investigated the effect that acetate supplementation had 
on purinergic enzymes and receptors in a rat model of neuroinflammation.  Our results 
show that acetate supplementation was able to modulate brain ecto-5’-nucleotidase 
(CD73) and adenosine kinase (AK) as well as the levels of the adenosine A2A receptor, 
which may describe a mechanism by which acetate exerts its observed anti-inflammatory 
and potentially neuroprotective effects.  The premise that bioenergetic stimulation can 
influence neuroinflammation has been demonstrated in various animal models of 
Alzheimer’s disease and Parkinson’s disease, as well as in Parkinson’s disease patients 
(Beal 2004).  Acetyl-L-carnitine, like acetate, bolsters mitochondrial metabolism in 
astrocytes and is neuroprotective in a rat model of traumatic brain injury (Scafidi et al. 
2010).  Similarly, the closest metabolic correlate of acetate supplementation, the 
ketogenic diet, also modulates brain mitochondrial metabolism, and is neuroprotective 
(Bough et al. 2006, Ruskin & Masino 2012) through a mechanism involving adenosine 
(Masino et al. 2010).  With 14 and 28 day prophylactic acetate supplementation we found 
that GTA was able to prevent LPS-induced reduction in CD73 levels in addition to 
increasing CD73 activity (Figures 7 and 8).  This suggests that GTA can elevate brain 
adenine nucleotide metabolism to potentially increase extracellular levels of adenosine.  
Furthermore, interventional acetate supplementation increased CD73 levels however 
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lower CD73 activity was observed with GTA as compared to the LPS group (Figure 9).  
Cortical stab wound and focal cerebral ischemia models of brain injury have 
demonstrated a biphasic alteration in CD73 expression and activity, where an initial 
decrease is followed by a distinct increase in expression and activity of CD73 during the 
post-injury period (Bjelobaba et al. 2011, Braun et al. 1997, Nedeljkovic et al. 2006).  
Thus, this suggests that the interventional GTA may require a longer treatment period to 
increase CD73 activity. 
Another key enzyme that regulates extracellular levels of adenosine is adenosine 
kinase (AK).  Although intracellular, the low Km of AK for adenosine (1.5–2.4 µM) 
(Arch & Newsholme 1978) combined with the bidirectional and equilibrative nature of 
adenosine transporters, allows AK to control adenosine uptake.  We found that 28 days of 
LPS-infusion increased AK levels as seen during traumatic brain injury and epilepsy 
(Aronica et al. 2011, Boison 2006) (Figure 8).  This increase was prevented by the long-
term prophylactic treatment which suggests that GTA in the presence of LPS is able to 
enhance extracellular adenosine availability by preventing the increase in its uptake and 
conversion to AMP.  However, this may lead to a scenario where, elevated adenosine 
levels become more susceptible to adenosine deaminase (ADA) mediated degradation to 
inosine, since ADA is a high capacity high Km (34 µM) enzyme (Arch & Newsholme 
1978, Fredholm 2007).  As these alterations may be cell-type specific, an in depth in vitro 
analysis of all purinergic enzymes is required to get a comprehensive view of how acetate 
alters adenosine metabolism. 
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Extracellular adenosine is an endogenous agonist for four different G protein-
coupled receptors (A1, A2A, A2B, and A3), of which the A1 and A2A receptors have the 
greatest relevance in the central nervous system (Fredholm et al. 2001, Klotz 2000).  The 
A1 receptor signal cascade generally suppresses neuronal activity, inhibits synaptic 
transmission, and reduces the activation and response of microglia (Fredholm et al. 
2005b, Haselkorn et al. 2010).  Adenosine A2A receptors are responsible for mediating 
LPS-induced neuroinflammation and neuronal dysfunction (Rebola et al. 2011).  
Antagonists of the A2A receptors have been shown to be anti-inflammatory in a number 
of CNS disorders (Brothers et al. 2010, Fredholm et al. 2005b, Rebola et al. 2011, Wei et 
al. 2011).  In specific regards to our model, it was found that the A2A receptor inhibitor 
caffeine attenuates LPS-induced neuroinflammation (Brothers et al. 2010).  We found 
that at 14 days, LPS-induced neuroinflammation caused a significant increase in A2A 
receptor levels compared to controls (Figure 7), in line with our previous findings that 
show an increase in IL-1β expression (Soliman et al. 2012b), which is known to increase 
A2A receptor levels (Trincavelli et al. 2002).  Fourteen day prophylactic acetate 
supplementation prevented this LPS-induced increase (Figure 7) in A2A receptors, which 
is in agreement with results demonstrating that GTA attenuates LPS-induced pro-
inflammatory release (Soliman et al. 2012b).  Since blockade of A2A receptors prevents 
IL-1β induced exacerbation of neuronal toxicity (Simoes et al. 2012), acetate 
supplementation has a combined effect of reducing IL-1β levels (Soliman et al. 2012b) 
and A2A receptors that could offer robust neuroprotection by attenuating 
neuroinflammation.  However, interventional acetate supplementation further increased 
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A2A receptor levels (Figure 9).  The reason for this difference is not clear yet but a 
bidirectional effect of A2A receptors in neuroinflammation has been described in the 
literature (Dai & Zhou 2011).  It is possible that interventional acetate supplementation 
started after significant morphological changes in neuroglia have already occurred may 
not be sufficient to counteract the LPS-induced elevation in A2A receptor levels.  
However, the ability of the A2A receptors to control neuroinflammation is dependent on 
local glutamate levels and is critical in determining whether their stimulation results in 
anti-inflammatory or pro-inflammatory effects (Dai & Zhou 2011).  Distinct pathological 
stages after injury respond to different A2A receptor modulators.  For example, during 
early spinal cord injury A2A receptor agonists offer neuroprotection while A2A receptor 
knockout was neuroprotective only during later injury stages (Li et al. 2006).  Thus, an 
alternative reasoning may be that the increase in A2A receptors observed with 
interventional GTA may be beneficial by enhancing the effects of endogenous adenosine 
during this 14 day treatment and contributes towards the anti-inflammatory effect of 
acetate supplementation.  However, to make this determination a thorough investigation 
of temporal changes in inflammatory markers, A2A receptors, and local glutamate levels 
with LPS and GTA is required.  A limitation of the interventional study was the lack of 
the aCSF control group which would have allowed us to determine whether the increase 
in A2A receptors was indeed an elevation from control levels.  Thus, future studies that 
examine the effect of interventional GTA strategy for longer treatment duration with 
proper controls are necessary.  Regardless, prophylactic acetate supplementation does 
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prevent the LPS-induced increase in A2A receptor levels, which may help to explain the 
mechanism by which GTA confers its anti-inflammatory effects. 
As stated before, acetate supplementation increases histone acetylation (Soliman 
& Rosenberger 2011) and reverses LPS-induced histone H3 at lysine 9 (H3K9) 
hypoacetylation in a model of neuroinflammation (Soliman et al. 2012b).  Histone 
hyperacetylation alters gene expression and also induces anti-inflammatory effects 
(Strahl & Allis 2000, Adcock 2007).  Therefore, it is reasonable to speculate that acetate 
induced histone acetylation may be a potential underlying mechanism involved in the 
modulation of adenosine metabolizing enzymes CD73 and AK as well as the levels of the 
adenosine A2A receptors, especially at the level of gene transcription.  Future studies will 
determine the link between acetate-induced histone acetylation changes and alteration in 
the levels of these proteins.  Using specific histone acetyltransferase inhibitors to block 
the effect of acetate on histone acetylation will allow us to determine its role in altering 
levels of adenosine metabolizing enzymes and receptors.  Further, by studying if 
acetylated H3K9 is associated with the gene promoters of adenosine metabolizing 
enzyme and receptor will determine if acetate-induced alteration in their expression is 
controlled by, acetylated H3K9.   
To better characterize the in vivo changes in purinergic enzymes and receptors 
considering the involvement of multiple cell types in purinergic signaling and the 
neuroinflammatory response, we investigated the effect of acetate on purinergic enzymes 
and receptors in isolated BV2 microglia and primary astrocyte cultures.  In addition to 
CD73 and AK enzymes, and A2A receptors, that were measured in vivo we also quantified 
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levels of ecto-apyrase (CD39), ADA, and adenosine A1 receptors.  Cultures were treated 
with sodium acetate (NaAc, 10mM) and sodium chloride (NaCl, 10 mM), as osmolarity 
control, both in the presence and absence of LPS (1000 ng/mL) to induce inflammation.  
We found that acetate was able to prevent or reduce LPS-induced changes in most of the 
adenosine metabolizing enzymes and receptors measured in BV2 microglia but not in 
primary astrocytes.  However, there were some similarities and dissimilarities between 
the in vivo and in vitro results that are discussed below.   
In contrast to the in vivo neuroinflammation model LPS increased CD73 levels in 
BV2 microglia indicating greater AMP breakdown into adenosine which was prevented 
by acetate in presence of LPS (Figure 10C and 10D).  Further, the CD39 levels in BV2 
microglia were not affected by LPS but acetate in presence of LPS reduced CD39 levels 
to below control levels suggesting reduced ATP and ADP breakdown to AMP (Figure 
10A and 10B).  On the other hand, we found that LPS increased AK levels similar to the 
in vivo results which were prevented by acetate treatment in presence of LPS (Figure 
11A and 11B).  This reduction in AK-mediated adenosine metabolism was further 
strengthened by a concomitant reduction in LPS-induced elevation of ADA levels by 
acetate to below control levels causing marked reduction in adenosine degradation 
(Figure 11C and 11D).  It is interesting to note that the effects of acetate on the enzymes 
that form adenosine (CD39 and CD73) and the ones that metabolize it (AK and ADA) are 
opposing to one another.  However, the Km values of AK (1.5–2.4 µM) and ADA (34 
µM) are at least 100- and 10-fold lower than CD39 (600 µM) and CD73 (245 µM), 
respectively (Arch & Newsholme 1978).  Thus, AK and ADA are rate-limiting at either 
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normal (20–50 nM) or pathological (100–1000 nM) levels of adenosine making their 
contribution to the regulation of extracellular adenosine levels more significant.  In other 
words, extracellular adenosine levels will be more sensitive to a 2-fold reduction in AK 
and ADA levels than a comparable reduction in CD39 and CD73 levels.  This may 
partially support the premise that acetate can increase extracellular adenosine availability.  
However, this is only theoretical and changes in enzyme activities and direct extracellular 
adenosine measurements are required to draw definitive conclusions.  LPS-stimulation in 
BV2 microglia increased A2A receptors which are in agreement with studies 
demonstrating that LPS induces A2A receptor mRNA (Orr et al. 2009) and protein levels 
(Gomes et al. 2013) in in vitro microglial cultures.  Acetate treatment further prevented 
LPS-induced elevation of A2A receptors (Figure 12C and 12D) similar to the in vivo 
results suggesting ramification and reduction in the inflammatory response (Orr et al. 
2009).  However, A1 receptor levels were also reduced to below control levels with 
acetate treatment in presence of LPS (Figure 12A and 12B).  This decrease in A1 
receptors may be reflective of an overall decrease in the inflammatory response in 
microglia. 
In primary astrocytes, we found that acetate in the presence of LPS increased 
CD73 levels indicative of greater adenosine formation similar to the in vivo 
neuroinflammation model (Figure 13C and 13D).  However, CD39 levels were only 
increased by LPS and not altered by acetate in presence of LPS (Figure 13A and 13B).  
In contrast to the in vivo results, while LPS did not affect AK levels, acetate increased 
AK levels in presence of LPS (Figure 14A and 14B).  Perhaps, this increase in 
 
100 
adenosine metabolism may be a compensatory mechanism to counteract the increase in 
CD39 and CD73 levels in order to replenish cellular adenine nucleotides.  Further, 
neither LPS nor acetate were able to alter ADA (Figures 14C and 14D) and A2A receptor 
levels (Figures 15A and 15B) in astrocytes while the A1 receptors were below the level 
of detection.  Although not definitive the effect of acetate in primary astrocytes suggests 
an overall increase in adenosine metabolism.  Combining the results obtained in primary 
astrocytes with those obtained in BV2 microglia raise multiple discrepancies as to how 
these changes relate to the in vivo results and whether they actually result in elevated 
adenosine levels.  To test this, we developed a HPLC based method with fluorescence 
detection to detect low adenine nucleotide and adenosine levels in cell cultures.   
The newly developed HPLC method (Figure 16) was used to accurately quantify 
intracellular adenine nucleotide levels and replicate the in vivo purine metabolism model 
in primary astrocyte cultures (Figure 17).  These measurements showed that acetate 
increased cellular energy charge ratio and PCr levels at 2 h of treatment supporting the 
bioenergetic hypothesis.  Additionally, it also suggests that beyond 3 h acetate treatment 
stimulates release of intracellular ATP which is in line with the purinergic metabolism 
hypothesis.  However, when the same method was used to quantify extracellular 
adenosine levels in primary astrocytes and BV2 microglia no significant changes were 
observed (Figure 18).  Thus, the study of purinergic metabolism in isolated BV2 
microglia and astrocytes appears to be much more complex than initially conceived.  It is 
possible that purinergic signaling is dependent upon paracrine communication between 
different cell types including microglia, astrocyte, and neurons.  Thus, a major limitation 
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of these experiments was studying the effects of acetate on microglia and astrocyte 
cultures in isolation.  In this regard, conflicting adenosine receptor functions can be 
observed in vitro, since it is difficult to maintain a homogenous glial population with 
defined activation state (Fredholm 2007).  Therefore, diverse co-culture paradigms 
including mixed glial cultures co-cultured in presence and absence of neurons, or 
organotypic slice cultures may serve as better model systems to characterize the effects of 
acetate on purinergic signaling.  Further, pretreatment of cultures with adenosine 
transport and degradation inhibitors can greatly enhance the half-life of extracellular 
adenosine.  However, the current results suggest that acetate may not alter the 
endogenous levels of adenosine but with the altered purinergic machinery may be able to 
respond to the release of endogenous nucleotides in a way that promotes anti-
inflammation and neuroprotection. 
In order to demonstrate whether acetate-induced acetyl-CoA can stimulate lipid 
synthesis, we investigated the effect of acetate in the presence and absence of LPS on 
fatty acid, phospholipid, and cholesterol content in BV2 microglia.  Not much is known 
about the fatty acid and phospholipid content of BV2 microglia.  However, a few studies 
have reported that stimulation of BV2 cells with saturated fatty acids results in a pro-
inflammatory response via Toll-like 4 receptor/NF-κB signaling pathways (Gupta et al. 
2012, Tracy et al. 2013, Wang et al. 2012).  As a proof-of-principle, we found that 
acetate increased the fatty acid (Table 3–5) and cholesterol (Table 8) content of BV2 
cells without altering individual phospholipid levels (Table 6 and 7).  These data support 
the hypothesis that acetate can stimulate fatty acid synthesis but future studies are 
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required to determine if the changes in fatty acid content are in fact due to an increase in 
de novo synthesis or reduction in β-oxidation.  Further, investigating the fatty acid 
composition of various phospholipid classes will provide more information as to how the 
fatty acids are being distributed inside the cell and understand the significance this has on 
membrane order and lipid signaling.  
Brain acetate availability is reduced in the white matter of multiple sclerosis 
patients (Li et al. 2013) and acetate supplementation increases myelin galactocerebrocide 
levels in a rat model of Canavan disease (Arun et al. 2010b).  In this regard, results of 
this study suggest that acetate can be used to not only directly replenish brain acetate 
levels but can also be utilized for lipid synthesis.  Acetate in presence of LPS at 2 h 
elevates cellular fatty acid content in a concentration-dependent manner with the greatest 
increase found at 5 mM followed by 1 and 10 mM NaAc+LPS.  The exact reason for a 
lower increase in fatty acid content with 10 mM NaAc+LPS is not yet clear.  However, it 
is known that de novo fatty acid synthesis and histone acetylation compete for the same 
acetyl-CoA pools (Galdieri & Vancura 2012).  Therefore, it is possible that higher acetate 
concentrations are utilized for other biochemical pathways as well as for histone 
acetylation.   
Alternatively, fatty acids synthesized as a result of higher acetate concentration 
may induce a negative feedback inhibition on lipid synthesis (Tong 2005).  The activity 
of the rate limiting enzyme, acetyl-CoA carboxylase (ACC), in lipid synthesis is 
controlled by phosphorylation.  Phosphorylation deactivates ACC and reduces malonyl-
CoA formation, the substrate for lipid synthesis.  The enzymes AMP kinase 
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phosphorylates ACC, which in turn is activated by AMP and long chain acyl-CoA levels 
(Tong 2005).  Both of which are formed as a result of elevated lipid synthesis and thus it 
is possible that they exert a phosphorylation mediated inhibition of ACC activity and 
lipid synthesis at higher acetate concentration.  Nonetheless, 1 and 5 mM acetate in 
presence of LPS increased the total fatty acid content by 23 and 34%, respectively.  It 
would be interesting to know whether longer treatment intervals with lower acetate doses 
can achieve greater elevation in the fatty acid content and distribution in vivo.   
Significant increases in the saturated fatty acids, PAM and STA, suggest an 
increase in the de novo fatty acid synthesis which can be further metabolized to other 
unsaturated fatty acids.  The lack of an increase in fatty acids having a acyl-chain length 
greater than 20 carbon atoms suggest that the observed changes may not a be a result of 
an increase in uptake of fatty acids from the culture medium or alternatively may reflect 
low levels of these fatty acid in the medium.  On the other hand, the increase in LNA, an 
essential fatty acid, must represent an increase in uptake of exogenous LNA.  This uptake 
may be enhanced in presence of LPS since it has been shown that in vivo LPS-infusion 
increases the brain concentrations of LNA and ARA (Rosenberger et al. 2004).  It is 
interesting to note that increase in the total and individual fatty acid contents were only 
observed in the NaAc+LPS group but not in the NaAc group.  This suggests that acetate 
by itself is unable to increase BV2 cell fatty acid content.  Studies have demonstrated 
conflicting results regarding the effects of LPS on β-oxidation of lipids in different 
tissues (Feingold et al. 2009, Feingold et al. 2008, Memon et al. 1998).  However, it is 
plausible that acetate treatment may reduce the β-oxidation of fatty acids rather than 
 
104 
stimulating de novo synthesis.  Further studies are required to determine the impact 
acetate treatment has on the β-oxidation and the de novo synthesis of fatty acids 
Fatty acids get incorporated into phospholipid pools and together with cholesterol 
control biological membrane order or fluidity (van Meer et al. 2008).  Thus, to determine 
if increased fatty acid content further alters the phospholipid content, we quantified levels 
of individual phospholipid classes.  Lack of changes in the phospholipid content at 2 h 
suggests that longer treatment periods or higher sample sizes may be required to detect 
appreciable changes in the total phospholipid content, although changes in the fatty acid 
composition of the individual phospholipid classes cannot be ruled out.  Alternatively, it 
is possible that the increase in fatty acids observed with acetate may be used for 
triglyceride and cholesteryl ester formation.  In this regard, LPS stimulation in murine N9 
microglia results in the formation of lipid droplets that are highly rich in triglycerides and 
cholesteryl esters (Khatchadourian et al. 2012).  Therefore, it will be interesting to study 
the effects of acetate on the fatty acid content of neutral lipids in different cellular 
compartments.  Because phospholipase A2 activation and eicosanoid synthesis occur 
utilizing specialized cellular phospholipid pools (Murakami et al. 2000) understanding 
the impact that acetate treatment has on fatty acid deposition and eicosanoid signaling is 
an exciting subject for future investigation.  
Radio-labeled acetate is incorporated into cholesterol (Hellman et al. 1954) 
however whether high concentrations of acetate can stimulate cholesterol synthesis is not 
known.  In this regard, our results demonstrate that 5 mM acetate significantly increases 
(11%) total cholesterol levels in BV2 microglia.  Absence of changes in cholesterol levels 
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with 10 mM acetate may partially be explained by the reversible lysine acetylation of the 
cytoplasmic 3-hydroxy- 3-methylglutaryl CoA synthase 1(HMGCS1), an enzyme 
catalyzing the first and critical step in cholesterol synthesis (Goldstein & Brown 1990).  
Protein lysine acetylation is emerging as a ubiquitous mechanism for regulating cellular 
metabolism (Zhao et al. 2010) and it has been demonstrated that deacetylation of the 
mitochondrial HMGCS2 by sirtuin 3 reduces its activity (Shimazu et al. 2010).  
Likewise, it has been demonstrated that the cytoplasmic HMGCS1 gets reversibly 
acetylated and is a substrate for cytoplasmic sirtuin 1-dependent deacetylation (Hirschey 
et al. 2011).  Thus, we speculate that higher concentrations of acetate may induce the 
acetylation of HMGCS1 resulting in its deactivation and prevent stimulation of 
cholesterol synthesis.  Since cholesterol is important in maintaining cellular membrane 
rigidity (Giusto et al. 2002) a proportionate increase, relative to the phospholipid content 
is essential.  Thus, future studies will test the effect of acetate on the cholesterol-to-
phospholipid ratio and the fatty acid composition of phospholipids with longer treatment 
durations.   
In addition to increasing fatty acid and cholesterol content, acetate 
supplementation has anti-inflammatory properties (Brissette et al. 2012, Reisenauer et al. 
2011) that can further augment its therapeutic efficacy in the treatment of 
neurodegenerative disorders that have a strong inflammatory component.  The underlying 
mechanism for the anti-inflammatory effects of acetate is thought to be mediated by an 
increase in histone acetylation and involves a disruption of the mitogen-activated protein 
kinases, Nf-κB, and eicosanoid signaling (Soliman et al. 2013a, Soliman et al. 2013b, 
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Soliman et al. 2012a, Soliman & Rosenberger 2011, Soliman et al. 2012b).  In this 
context, we demonstrated that in BV2 microglia acetylated H3K9 is associated with the 
promoter regions of cyclooxygenase 1 and 2, interleukin-1β and p65 genes that are 
involved in inflammation (Soliman et al. 2013b).  Therefore, we selected BV2 cells to 
study the effect of different acetate concentrations on the acetylation-state of nuclear 
histones.  We expanded the scope of this study to include H4S1/K5/K8/K12 acetylation 
in addition to H3K9 and examined the time required by 10 mM acetate to alter the 
acetylation-state of these histones.  These results suggest that acetate-induced increase in 
H3K9 acetylation requires 4 h to show a significant change however H4 acetylation starts 
as soon as 0.5 h following acetate treatment.  Interestingly, H4 acetylation increased in a 
time-dependent manner suggesting a progressive increase in multiple lysine and/or serine 
residues that get acetylated with time.  Further, the concentration-response effect of 
acetate on the acetylation-state of H3 and H4 showed that the minimum concentration of 
acetate required to stimulate histone acetylation was 5 mM for both H3 and H4.  
Collectively, these results and the effect of acetate on lipid content suggest that acetate-
induced increase in fatty acid content may precede histone acetylation.  This conclusion 
is supported by studies demonstrating that attenuated expression of ACC, the rate-
limiting enzyme in de novo fatty acid synthesis, increases global histone acetylation and 
alters transcriptional regulation (Galdieri & Vancura 2012). 
In conclusion, acetate supplementation stimulates purine metabolism in whole 
brain and glial cultures which may contribute to the anti-inflammatory effects of glyceryl 
triacetate.  However, future studies are required to more conclusively establish the role of 
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acetate-induced purine metabolism in altering neuroinflammation for designing targeted 
drug therapies for the treatment of neurodegenerative disorders.  Furthermore, although 
preliminary, acetate increases fatty acid content and cholesterol levels in BV2 microglia.  
Future studies will test the effect of acetate supplementation in demyelinating rodent 
models such as the experimental-autoimmune encephalomyelitis and will be instrumental 
in developing therapeutic strategies for the treatment of diseases like multiple sclerosis 
and Canavan disease.  Finally, differential effects of distinct acetate concentrations on 
lipid synthesis and histone acetylation may provide the foundation for the development of 
novel therapeutic strategies in the treatment of disorders requiring either enhanced lipid 
synthesis, or attenuation of inflammation. 
 
Summary and Significance 
Neuroinflammation can lead to neuronal dysfunction and degeneration as found in 
many neurological diseases such as Alzheimer, Parkinson, Huntington, Amyotrophic 
lateral sclerosis, and Multiple sclerosis.  Although impaired brain energy metabolism and 
neuroinflammation are important contributing factors of neurodegeneration, therapeutic 
strategies targeting energy impairment to reduce injury have not been exploited.  Our lab 
has demonstrated that acetate supplementation is anti-inflammatory and neuroprotective 
in rat models of neuroinflammation (Reisenauer et al. 2011) and Lyme neuroborreliosis 
(Brissette et al. 2012).  Other studies have demonstrated its potential as a metabolic 
support during brain injury (Arun et al. 2010a), it improves the tremor phenotype in a 
Canavan disease model (Arun et al. 2010b), and has also been shown to possess growth 
arresting properties in gliomas (Tsen et al. 2013).  However, the exact mechanism(s) 
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involved in the beneficial effects of acetate supplementation are not well understood.  
The focus of this work was to better understand the mechanisms by which an increase in 
brain acetyl-CoA levels through purine and lipid metabolism can attenuate inflammation 
and offer neuroprotection.   
Acetate supplementation in rats increases plasma acetate and brain acetyl-CoA 
levels (Reisenauer et al. 2011) and this increase in acetyl-CoA levels is thought to be the 
fundamental step in propagating the biological effects of acetate.  Since acetyl-CoA is a 
ubiquitous substrate for several biochemical pathways such as carbohydrate, protein, and 
lipid metabolism, there can be multiple mechanisms (Figure 21) underlying the 
protective effects of acetate supplementation.  Thus, gaining a better understanding of 
acetate’s role in altering acetyl-CoA-dependent metabolic pathways can provide 
mechanistic insights into the protective effects of acetate supplementation.  Earlier our 
lab characterized the effects of acetate supplementation in altering brain and glial culture 
histone and non-histone protein acetylation, and inflammatory signaling (Soliman et al. 
2013a, Soliman et al. 2013b, Soliman et al. 2012a, Soliman & Rosenberger 2011, 
Soliman et al. 2012b).  Alternatively, radio-labeled acetate gets incorporated in the TCA 
cycle, and the fatty acid and cholesterol synthesis pathways (Hellman et al. 1954, 
Howard et al. 1974, Wyss et al. 2011), however the effect that increasing acetate 
availability has on energy or purine and lipid levels has not been studied.  Moreover, the 
link between acetate’s potential to increase brain energy or purine and/or lipid 









Figure 21:  Acetate supplementation stimulates acetyl-CoA pathways. 
Acetate supplementation increases brain acetyl-CoA levels which stimulate three primary pathways: TCA cycle, protein acetylation, 
and lipid synthesis.  We have shown that acetyl-CoA through the TCA cycle increases brain PCr and reduces AMP levels.  Purines 
and their breakdown product, adenosine are potent modulators of inflammation.  In this regard, acetate alters the levels and activity of 
enzymes, and receptors involved in purine metabolism and signaling.  Since acetate increases acetylation of histone and non-histone 
proteins which alter gene expression we postulate that changes in histone acetylation are responsible for the altered purinergic enzyme 
and receptor levels observed with acetate supplementation.  We further believe that this altered purinergic machinery results in altered 
purinergic signaling whereby the neuroinflammatory balance is shifted towards anti-inflammation.  Furthermore, acetate increases the 
fatty acid and cholesterol content in BV2 microglia which suggests that acetate has the potential to increase lipid deposition in 
demyelinating or insufficient myelin synthesis disorders such as multiple sclerosis and Canavan disease. 
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This study investigates key aspects of the two major acetyl-CoA pathways: the 
tricarboxylic acid (TCA) cycle, and lipid synthesis.  The TCA cycle is responsible for 
energy generation and linked to purine metabolism.  Purines and their degradation 
product, adenosine are important signaling molecules that mediate inflammation.  On the 
other hand, lipids are important components of biological membranes and also play 
important roles in energy storage, signal transduction, and post-translational protein 
modifications.  Thus, we proposed that acetate supplementation by increasing acetyl-CoA 
levels stimulates purine and lipid metabolism which in turn reduce inflammation and 
increase lipid deposition.   
To begin to test this hypothesis, we measured the effect that short-term acetate 
supplementation has on brain purine levels and demonstrated that acetate not only 
increases brain energy reserves but can potentially alter brain purine metabolism (Bhatt et 
al. 2013).  Using long-term acetate supplementation this study also highlighted 
differences between acetate supplementation and its close metabolic correlate, the 
ketogenic diet.  Results of this study further raised the possibility that neurons could also 
utilize acetate at least at higher concentrations challenging the accepted convention of 
preferential astrocytic or glial acetate utilization.  Furthermore, using different acetate 
supplementation regimens we tested the potential of acetate in altering purinergic 
enzymes and receptors.  In these studies, we demonstrated that both prophylactic and 
interventional acetate supplementation modulate LPS-induced alterations in the levels 
and activity of enzymes involved in adenosine metabolism, and adenosine receptor levels 
(Smith et al. 2013).  These findings are important because they suggest that acetate 
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supplementation can be used to enhance the effects of an endogenous anti-inflammatory 
molecule, adenosine.  To further determine the mechanism(s) by which acetate 
supplementation alters purine metabolism and inflammation we used in vitro cell cultures 
of BV2 microglia and primary astrocytes, the cells types involved in initiating and/or 
mediating the inflammatory response.  Although we found that the in vitro acetate 
treatment reversed LPS-induced expression of enzymes and receptors involved in 
adenosine metabolism, these data did not completely correspond to our in vivo results.  
Findings from these experiments supported the hypothesis that acetate can alter 
purinergic metabolism and underscored the importance of paracrine signaling between 
different brain cell types for the study of purinergic signaling.   
Further, we developed a highly sensitive high performance liquid 
chromatography-based method capable of detecting and accurately quantifying low levels 
of adenine nucleotides and adenosine in cell cultures (Bhatt et al. 2012).  Using this 
method we found that acetate initially increased astrocytic energy levels, followed by 
reduction in intracellular adenine nucleotides while maintaining a normal energy charge 
ratio.  These data strengthen the premise that acetate alters energy and purine metabolism 
and further suggest that in astrocytes acetate can increase adenine nucleotide release 
which are substrates for extracellular purinergic enzymes and agonists for purinergic 
receptors.  However, using the same method we were unable to find appreciable changes 
in the extracellular levels of adenosine in primary astrocytes as well as BV2 microglia.  
These studies suggest that either acetate does not affect extracellular adenosine levels or 
if it does increase them then elaborate in vitro models need to be designed that are 
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amicable to greater control over adenosine metabolism with intact intercellular 
communication.  Regardless of whether acetate can directly increase in vitro adenosine 
levels or not, our in vivo results suggest that acetate can modulate LPS-induced changes 
in the purinergic setup that is more suited to alter the response to release of endogenous 
adenosine and adenine nucleotides.  These studies further accentuate the importance of 
studying the purinergic P2X and P2Y receptor mediated pro-inflammatory component of 
purinergic signaling.  Lastly, our study of the effects of acetate on fatty acid, 
phospholipid, and cholesterol content showed that acetate-induced acetyl-CoA can 
increase fatty acid and cholesterol content in BV2 cells (Bhatt & Rosenberger 2013).  
This proof-of-principle experiment suggested that acetate supplementation may be 
utilized for stimulating lipid synthesis.  Further, these experiments also provide 
background information required for the development of novel therapeutic strategies that 
can selectively target disorders requiring either enhanced lipid synthesis, or attenuation of 
inflammation. 
Collectively these studies demonstrate that acetate supplementation increases 
purine metabolism and lipid content in brain and glial cultures and supports the 
hypothesis that these in turn may contribute to the anti-inflammatory effects and lipid 
deposition potential of acetate.  This dissertation work is significant because it provides 
fundamental knowledge required for the development of acetate supplementation as an 




















A2AR Adenosine A2A receptor 
ACC Acetyl-CoA carboxylase 
aCSF Artificial cerebral spinal fluid 
ADA Adenosine deaminase 
ADO Adenosine 
ADP Adenosine diphosphate 
AK Adenosine kinase 
AMP Adenosine monophosphate 
AMPCP α, β-methylene adenosine diphosphate 
ANOVA Analysis of variance 
APP α Amyloid-β precursor protein 
ARA Archidonate 
ATP Adenosine triphosphate 
BSA Bovine serum albumin 
CD 14 Cluster of differentiation 14, a pattern recognition receptor. 
CD 39 Ecto-apyrase 
CD73 Ecto-5’-nucleotidase 
CerPCho Sphingomyelin 







free Hanks balanced salt solution 
Cn Creatinine 




DMEM/F12 Dulbe’co's Modified Eagle Medium/Nutrient Mixture F-12 
DMSO Dimethyl sulfoxide 
ECR Energy charge ratio 
EDTA Ethylenediaminetetraacetic acid 
EGTA Ethyleneglycoltetraacetic acid 
EPA Eicosapentaenoate 
EtnGpl Ethanolamine glycerophospholipids 
FAME Fatty acid methyl esters 
FAS Fatty acid synthase 
FBS Fetal bovine serum 
Freon Trichlorotrifluromethane 
GFAP Immuno-fluorescence staining 
GTA Glyceryl triacetate 
GTP Guanosine triphosphate 
H3 Histone 3 
H3K9 Histone 3 acetylated at lysine 9 
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H4 Histone 4 
H4S1/K5/K8/K12 Histone 4 acetylated at serine 1, and lysine 5, 8, or 12 
HEPES 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid, buffer 
HIP n-hexane:2-propanol (3:2, by Vol) 
HPLC High performance liquid chromatography 
IL-1β Interleukin-1β 
KH2PO4 Potassium phosphate 
LDH Lactate dehydrogenase 
LNA Linoleate 
LPS Lipopolysaccharide 
NaAc Sodium acetate 
NaCl Sodium chloride 
NAD Nicotinamide adenine dinucleotide 
NMDA N-Methyl-D-aspartic acid 
OLA Oleate 
PAM Palmitate 





PVDF Polyvinylidene fluoride 
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ROS Reactive oxygen species 
SD Standard Deviation 
SDS Sodium dodecyl sulfate 
STA Stearate 
TBAP Tetrabutylammonium phosphate 
TBS-T Tris buffered saline containing Tween 20 
TCA cycle Tricarboxylic acid cycle 
TEMED N,N,N’,N’-tetramethylene-diamine 
TLC Thin layer chromatography 
TLR 4 Toll-like receptor 4 
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